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Abstract 
Leishmania are protozoan endoparasites belonging to the family of Trypanosomatidae 
and are responsible for a widespread group of diseases collectively known as 
leishmaniases. These diseases encountered in tropical, subtropical areas of the world 
and middle Asia range from self-healing cutaneous leishmaniasis to lethal visceral 
leishmaniasis. The variability of clinical manisfestations results from both the diversity of 
Leishmania species and the immune response of its host. Over 12 million of people are 
infected world wide. No effective vaccines, drugs or chemoprophylaxe exists to protect or 
heal leishmaniases. 
The search of more effective and rational drug treatments led researchers to investigate 
the role of surface molecules in the parasite infectivity. Leishmania parasites are 
surrounded by a dense glycocalyx involved in parasite virulence. The cell surface 
glycoconjugates protect the parasites from hostile environments and are involved in 
subversion of the host immune response. Interestingly, Leishmania glycoconjugates 
contain galactofuranose (Galf), an uncommon monosaccharide expressed at the cell 
surface of many human pathogens. Galf is found in a variety of bacteria (e.g. Escherichia 
coli, Klebsiella pneumoniae, Mycobacteria ssp.), fungi (e.g. Aspergillus species) or 
protozoan parasites (Leishmania species, Trypanosoma cruzi). Because Galf residues 
are often present in structures considered essential for virulence but are lacking in 
metazoans, the enzymes involved in its biosynthesis could be attractive targets for 
chemotherapy. In recent years, different enzymes involved in Galf metabolism have been 
characterised in bacteria. Galf was shown to arise from the action of the UDP-
Galactopyranose mutase (UGM). This flavoprotein catalyses the interconversion of UDP-
Galactopyranose (UDP-Galp) into UDP-Galactofuranose (UDP-Galf), which is the donor 
of galactofuranose to the various galactofuranosyltransferases involved in 
glycoconjugate and polysaccharide synthesis. Although the existence of such enzyme in 
eukaryotes was suspected, it had thus far not been identified. Moreover, with the 
exception of a putative galactofuranosyltransferase of Leishmania, all other enzymes 
involved in Galf metabolism of eukaryotes are still unknown. 
Here we report the characterisation of Leishmania major UGM and the determination of 
its role in glycoconjugate biosynthesis and parasite virulence by a targeted gene deletion 
approach. In Leishmania major, Galf is present in the GPI-anchor of the abundant cell 
surface Lipophosphoglycan (LPG) and the Glycosylinositolphospholipids (GIPLs). 
Consequently, we observe the absence of LPG and the presence of truncated GIPLs 
lacking Galf in our ∆glf mutant. Other glycoconjugates were, however, unaffected. The 
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virulence of the ∆glf mutant was assessed by lesion formation of Balb/c mice after 
inoculation with the parasites. Remarkably mice inoculated with the ∆glf mutant did not 
develop any lesion, indicating the importance of this gene for the pathogen survival and 
proliferation in the mammalian host. This study represents the first investigation of the 
role of galactofuranose in eukaryotes. 
 
Keywords:  Galactofuranose, UDP-Galactopyranose mutase, Leishmania 
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Zusammenfassung 
Leishmanien sind einzellige Endoparasiten der Familie Trypanosomatidae und 
verursachen die weit verbreitete Krankheit Leishmaniose. Das Hauptverbreitungsgebiet 
der Krankheit liegt in den Tropen, Subtropen und Zentral Asien. Das Krankheitsbild reicht 
von der selbst heilenden kutanen Leishmaniose bis hin zur tödlichen viszeralen Form. 
Die Variabilität in der klinischen Erscheinungsform hängt zum einen von der Artenvielfalt 
der Leishmanien und zum anderen von dem Immunstatus des Wirtes ab. Über zwölf 
Millionen Menschen sind weltweit infiziert. Derzeit existiert weder ein Impfstoff oder eine 
effektive medikamentöse Behandlungsmöglichkeit noch eine Chemoprophylaxe, die vor 
Leishmaniose schützt oder die Krankheit heilt. Die Suche nach effektiveren 
Behandlungsmöglichkeiten führte zu der Untersuchung von Oberflächenmolekülen und 
deren Beteiligung an der Infektiosität des Parasiten. Verantwortlich für die Virulenz der 
Leishmanien ist die Glykokalyx, die den Parasiten umgibt. Sie schützt den Parasiten im 
Sandfliegen-Vektor und vor der Immunantwort des Wirtes. Interessanterweise enthalten 
die Glykokonjugate der Leishmanien das seltene Monosaccharid Galactofuranose (Galf), 
das auch auf Zelloberflächen von vielen Humanpathogenen exprimiert wird. So kommt 
Galf z.B. in verschiedenen Bakterien (z.B. Escherichia coli, Klebsiella pneumoniae, 
Mycobacteria ssp.), in Pilzen (z.B. Aspergillus ssp.) oder auch in einzelligen Parasiten 
(Leishmania ssp., Trypanosoma cruzi) vor. Da Galf in Strukturen vorhanden ist, die für 
die Virulenz von Humanpathogenen verantwortlich sind und die in den Metazoa 
vollständig fehlen, stellen Enzyme in der Biosynthese des Zuckers potenzielle 
Ansatzpunkte für die Entwicklung von Medikamenten dar. In den letzten Jahren wurden 
verschiedene Enzyme im Stoffwechselweg der Galf in Bakterien charakterisiert. Es 
konnte gezeigt werden, dass Galf von dem Enzym UDP-Galactopyranose mutase (UGM) 
gebildet wird. Dieses Flavoprotein katalysiert die reversible Umwandlung von UDP-
Galactopyranose und UDP-Galactofuranose. Die UDP-Galactofuranose ist der Vorläufer 
der Galactofuranose, die von der Galactofuranosyltransferase zu den Glykokonjugaten 
und Polysacchariden transportiert wird. Die Existenz der UGM wurde schon lange auch 
in Eukaryoten vermutet, aber so weit noch nicht identifiziert. Eine Ausnahme bildet die 
Galactofuranosyltransferase in Leishmanien. Alle anderen Enzyme in der Biosynthese 
der Galactofuranose in Eukaryoten sind jedoch unbekannt.  
In dieser Arbeit wurde sowohl die UGM aus dem Eukaryoten Leishmania major 
charakterisiert, als auch die Rolle des Enzyms in der Biosynthese der Glykokonjugate 
untersucht. Um die Bedeutung des Enzyms für die Virulenz des Parasiten zu ermitteln, 
wurden Deletionsmutanten (∆glf) hergestellt.  
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In Leishmania major ist Galf zentraler Bestandteil im Glycosyl-Phosphatidylinositol – 
Anker des prominent vertretenen Lipophosphoglykan (LPG), sowie der 
Glycoinositolphospholipide (GIPLs). Folglich enthielten die ∆glf Mutanten kein LPG und 
exprimierten nur verkürzte GIPLs, während die anderen Glykokonjugate unverändert 
blieben. Die Virulenz der ∆glf Mutanten wurde durch Bildung von Läsionen in Balb/c 
Mäusen nach Inokulation des Parasiten untersucht. Bemerkenswerterweise entwickelten 
die Mäuse, die mit den ∆glf Mutanten infiziert worden waren, keine Läsionen, was die 
Wichtigkeit des Gens für das Überleben und die Vermehrung des Parasiten im Säugetier 
unterstreicht. Die Untersuchungen dieser Arbeit bieten erstmalig Daten über die Funktion 
der Galf innerhalb der Eukaryoten. 
 
 
Schlagwörter:       Galactofuranose, UDP-Galactopyranose mutase, Leishmanien 
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1 Introduction 
1.1 Leishmania  and Leishmaniases 
Leishmania (L.) are protozoan endoparasites belonging to the order of the Kinetoplastida 
and the family of Trypanosomatidae (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Classification of the genus Leishmania.  
 
The genus Leishmania includes almost 30 different species, of which 21 are known to 
infect people, causing disease symptoms collectively known as leishmaniasis (Lane, 
1993). They infect numerous mammalian species acting as reservoir, and are 
propagated through the bite of different species of sand fly belonging to the genus 
Phlebotomus or Lutzomya, depending on the region. Leishmania parasites present two 
distinct morphological stages: the intracellular amastigote and the extracellular 
promastigote stage (Figure 2). The amastigotes have a round or oval body of about 2-6 
µm in diameter, containing a large nucleus, a kinetoplast and a residual flagellum 
attached to the blepharoblast. They multiply within the parasitophorus vacuoles of 
macrophages in the mammalian host. The promastigotes have a long and slender body 
(about 15-30 µm by 2-3 µm), with a central nucleus, a kinetoplast and a long anterior 
flagellum. They can be further classified as procyclic promastigotes, which multiply in the 
gut of the sand fly, or as the infective metacyclic promastigotes, which are found in the 
mouth part and anterior gut and do not divide (Farrel et al., 2002).  
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Figure 2: Morphology of Leishmania.  
 
The life cycle of the parasites is shown in Figure 3. The infective metacyclic 
promastigotes are transmitted by the bite of an infected female sand fly to the 
mammalian host. The parasites produce a chemotactic factor (LCF) that recruits 
polymorphonuclear neutrophil granulocytes (PMN) (Laskay et al., 2003). The latter 
phagocyte Leishmania and release IL-8 that amplifies the migration of PMN to the site of 
infection, as well as the monocyte attractant MIP-1β. Recruited cells of the 
monocyte/macrophage lineage ingest apoptotic PMN harboring viable parasites. This 
infection strategy is one of the sophisticated mechanisms used by Leishmania to silence 
the antimicrobial functions of macrophages. Once inside the macrophage, the parasites 
transform into non motile amastigotes and proliferate despite the acidic pH until the 
macrophage burst. The released parasites infect surrounding macrophages, which 
results in disease development. During a blood meal on an infected person, a sand fly 
can ingest infected macrophages or free amastigotes. These parasites transform rapidly 
into motile procyclic promastigote that attach to the midgut of the sand fly vector to avoid 
excretion and proliferate. They undergo a process called metacyclogenesis during which 
they convert into non-dividing infective metacyclic promastigotes (Sacks, 1989), detach 
from the midgut of the sand fly vector and migrate to the pharynx and oesophagus. 
During another blood meal the metacyclic promastigotes are transferred with the saliva of 
the sand fly which supports the establishment of the parasites infection in the mammalian 
host most likely by inhibition of oxidative metabolic processes and antigen presentation 
(Lerner et al., 1991, Theodos et al., 1991).  
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Figure 3: Bigenetic life cycle of Leishmania Leishmania are dimorphic parasites present in two 
morphological stages: the intracellular amastigotes that survive and proliferate inside mammalian 
macrophages, and the extracellular promastigotes that multiply in the sand fly vector. 
 
Leishmania parasites are the etiologic agents of leishmaniases, a widespread group of 
diseases encountered in tropical, subtropical areas of the world and middle Asia. Old 
world species of Leishmania, such as L. donovani and L. major cause pathology from 
southern Europe to Africa, the Middle East, and throughout Asia, whereas New World 
species (e.g. L. mexicana, L. amazonensis and L. chagasi) are found throughout South 
America and Central America as far north as the United States. Leishmaniasis presents 
itself in four different clinical forms. The variability of the clinical manifestations results 
from both the diversity of Leishmania species and the immune response of its host. All 
forms can have devastating consequences. Visceral leishmaniasis (kala azar), caused by 
the species L. donovani or L. chagasi, is the most severe form of the disease. The 
parasites infect the liver, spleen and bone marrow leading to death if not treated. 90% of 
annual cases of visceral leishmaniasis are reported in Bangladesh, Brazil, India and 
Nepal. The cutaneous forms of leishmaniasis are the most common and represent 50 to 
75% of all new cases (WHO), 90% of which occur in Afghanistan, Brazil, Iran, Peru, 
                                                                                                               Introduction 
 8
Saudi Arabia and Syria and are caused by L. major and the L. mexicana subgenus. An 
ulcer forms at the site where a sand fly has bitten. The parasite is usually only found in 
the region of the ulcer but in some species, it also infects the lymphatic system, causing 
numerous skin wounds along the lymphatic ducts. The lesions are self-healing but leave 
the patients permanently scarred. The main causative species are L. major, L. mexicana, 
L. tropica, L.aethiopica, L. guyanensis and L. panamensis. The Viannia subgenus (e.g. L. 
braziliensis, L. panamensis) is encountered solely in the Americas and is responsible for 
the clinical form named mucocutaneous leishmaniasis (also called espundia) 
(Descoteaux and Turco, 1999) characterised by extensive and disfiguring destruction of 
mucous membranes of the mouth, nose and throat cavities. Healing is never 
spontaneous and untreated patients can die from secondary infections. The last form is 
called diffuse cutaneous leishmaniasis and is characterised by widespread papules or 
nodules in the skin all over the body. It never heals spontaneously and tends to relapse 
after treatment. In Africa (Kenya, Ethiopia) it is caused mainly  by L. aethiopica and in 
Central America and northern South America it is caused mainly by L. amazonensis. In 
2000, the World Health Organization estimated that over 12 million people are infected 
by the various Leishmania species in 88 countries and hundreds of million are at risk. 
There is no vaccine against leishmaniases. Available drugs are in most cases not 
efficient or reliable, very expensive and cause strong side effects. Another problem is the 
ever-increasing drug resistance. Standard therapy of leishmaniasis consists of repeated 
injections of pentavalent antimonials, associated with important side effects. Many 
parasites are resistant against this treatment. If these drugs are not effective, the second 
line drugs are pentamidine and amphotericin B. They are only successful when injected 
at high doses and are costly (Croft and Coombs, 2003). The recently introduced 
alkylphospholipid Miltefosin, originally developed as anticancer agent, is active orally 
against visceral leishmaniasis but its side effects do not allow application under all 
circumstances, e.g. in pregnancy or in severely malnourished patients. Vector and 
reservoir controls may be useful under certain conditions but are not applicable in every 
epidemiological setting and require infrastructure and vigilance beyond the capability of 
many endemic countries. There is thus a clear need for a vaccine or for more effective 
and rational drug treatments that are based on the fundamental knowledge of the 
pathogen biology.  
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1.2 Leishmania surface  
1.2.1 Composition of Leishmania glycocalyx 
The densely organised parasite surface is the primary interface with the insect and 
mammalian hosts and plays essential roles in the sophisticated mechanisms that 
Leishmania has evolved to survive and proliferate in the highly hostile environment 
associated with its life style. Procyclic promatigotes are covered by a 7 nm thick 
glycocalyx. This cell coat reaches at least 17 nm in metacyclic parasites but is almost 
completely absent from amastigotes. This jacket comprises several glycoconjugates 
such as the lipophosphoglycan (LPG), glycosylphosphatidylinositol (GPI)- anchored 
proteins and free glycosylinositolphospholipids (GIPLs) (Figure 4). Additionally, 
Leishmania secrete various molecules such as the proteophosphoglycans (PPGs) that 
have also directly been linked to parasite survival and pathogenicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Surface glycoconjugates of Leishmania promastigotes: Leishmania promastigotes are coated 
with a thick glycocalyx comprised of LPG, GIPLs, GPI-anchored proteins and membrane bound PPGs. 
Additionally they secrete PPGs. Gal, galactose; Galf, galactofuranose; Man, mannose; P, phosphate, PI, 
phosphatidylinositol, R, side chain modification; Glc, glucose; GlcN, glucosamine; EtN, ethanolamine. 
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1.2.1.1 The lipophosphoglycan  
LPG is the predominant cell surface glycoconjugate of Leishmania promastigote. It is 
present all over the surface, including the flagellum. Found in all Leishmania species, 
LPG is composed of four domains, (1) a 1-O-alkyl-2-lyso-phosphatidyl-myo-inositol-
anchor, (2) a conserved glycan core, (3) a backbone of 15 to 30 
Galß1,4Manα1−phosphate repeat units and (4) an oligosaccharide cap structure (Figure 
5) (Turco et al., 1992,  Descoteaux  and Turco, 1999, McConville et al., 1993, Guha-
Niyogi et al., 2001).  
 
 
 
 
 
Figure 5: Structure of LPG from L. major promastigote highlighting the presence of a Galf residue in 
the glycan core. R = H; Galβ(1-; Galβ(1-3)Galβ(1-; Araβ(1-2)Galβ1-(McConville et al., 1990b, McConville et 
al., 1992). 
 
Leishmania species differ remarkable by the presence of glycan side chains as well as 
by their composition and positioning on the LPG core structure (McConville et al., 1995). 
LPG of L. major, for example, is highly branched with oligosaccharides containing β-Gal, 
β-glucose and β-arabinose (Ara) residues attached to the C3 hydroxyl of the repeat unit 
Gal, whereas that of L. donovani does not possess any side chains. Furthermore, the 
structure of LPG differs between procyclic and metacyclic promastigotes, being 
significantly longer in the latter. The structural changes associated with the acquisition of 
infectivity during metacyclogenesis, have been particularly well described in L. major. In 
this species, the doubling of repeat units is associated with an increased frequency of 
terminal β-arabinose in LPG side chains. The thickening of glycocalyx reflects these 
changes. Similarly the differentiation of promastigotes into amastigotes is associated with 
a strong down regulation of LPG that is almost absent from amastigotes and is reflected 
by the lack of conspicuous surface glycocalyx. Comparable developmental changes in 
LPG structure also occur in L. donovani and L. chagasi. However, in L. donovani, 
changes in LPG conformation rather than side chain modifications are thought to 
regulate the stage specific expression of surface glycan epitopes. In contrast, recent 
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studies suggest that cellular levels of LPG decrease drastically in L. mexicana metacyclic 
promastigotes.  
 
1.2.1.2 GPI-anchors 
Although some of the plasma membrane proteins of the parasitic protozoa use 
transmembrane polypeptide anchors, most of the major cell surface proteins of these 
organisms are GPI-anchored. These proteins are functionally diverse and include coat 
proteins, surface hydrolases and receptors. In all GPI-anchors characterised to date 
(from protozoa, yeast, fish, mammals, etc.) the C-terminus of the protein is linked via 
ethanolamine phosphate to a glycan with the conserved backbone sequence Manα1-
2Manα1-6Manα1-4GlcN, which in turn is linked to the 6-position of the myo-inositol ring 
of phosphatidylinositol. The tetrasaccharide backbone may be substituted with other 
sugars in a species and stage specific manner. The GPI-anchored 58-65kDa 
metalloprotease termed GP63 or leishmanolysin is abundantly expressed by all 
Leishmania promastigotes and has thus been widely studied. Like LPG, GP63 shows 
marked heterogeneity among Leishmania species (Medina-Acosta et al., 1993). The 
major promastigote isoform is modified with high mannose N-linked glycans and a GPI 
anchor and is proteolytically processed during transit to the cell surface. Like LPG, the 
expression of GPI-anchored proteins is mostly downregulated as promastigote 
differentiate to amastigotes suggesting that these proteins are primarily required for life in 
the sand fly vector (Naderer et al., 2004). 
 
1.2.1.3 GIPLs 
The glycosylinositolphospholipids (GIPLs) are the main class of glycolipids synthesised 
by all developmental stages of Leishmania parasites. They are members of the GPI 
family by virtue of containing the core sequence Manα1-6GlcNα1-6myo-inositol. Three 
different lineages of GIPLs have been distinguished, which are expressed in markedly 
different levels in different species or developmental stages. The type 1 and 2 GIPLs 
have glycan headgroups which are structurally related to GPI protein anchors (Manα1-
2Manα1,6Manα1,4GlcNα1,6-PI) and the LPG anchor respectively (Galα1,6Galα1,3 
Galfα1,3Manα1,3Manα1,4GlcNα1,6-PI), while the hybrid type has branched glycan 
headgroups containing elements of both anchors Manα1,6(Manα1,3)Manα1,4GlcNα1,6-
PI (McConville et al., 1993). However they are far more abundant than GPI- and LPG- 
anchors, contain distinct lipid moieties and are clearly end products. These glycolipids 
cover a large proportion of the plasma membrane and are likely to be the major surface 
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components exposed on the amastigote stage. Unlike LPG which is continuously shed 
from the membrane, GIPLs have a long half life. Moreover the type-2 GIPLs present in L. 
major are highly immunogenic due to the presence of galactofuranose (Figure 6). 
 
 
 
 
 
 
 
Figure 6: Structure of GIPLs from L. major highlighting the presence of a Galf residue. R = H; Galα(1-
3); Galα(1-6)Galα(1-3); Galβ(1-3)Galα(1-3); McConville et al., (1990). 
 
1.2.1.4 PPG 
Cell surface and secreted proteophosphoglycans (PPGs) are an expanding family of 
highly glycosylated Leishmania proteins (Ilg, 2000) containing similar phosphoglycans 
chains to those found in LPG (Jaffe et al., 1990, Bates et al., 1990). 
Phosphoglycosylation is the most abundant type of protein glycosylation in these 
parasites and is initiated by the transfer of Manα1-phosphate to serine and threonine 
residues in the polypeptide backbone (Moss et al., 1999). This mannose phosphate 
residue is then extended with mannose or with one or two Galß1,4Manα1−phosphate 
repeating units (Ilg et al., 1994). PPG profiles of different Leishmania species and 
developmental stage can vary markedly (Ilg et al., 1994 and 1996). For example, L. 
mexicana promastigotes secrete three distinct classes of PPG (two forms of secreted 
acid phosphatase and a filamentous PPG) while amastigotes only secretes one form of 
PPG that accumulates in the parasitophorus vacuole and extracellular milieu of the 
lesion. L. major, however, secretes fewer PPGs than L. mexicana, although some strains 
express a GPI-anchored form of PPG on their cell surface (Ilg et al, 1999).   
 
1.2.2 Function of the surface glycoconjugates of L. major in the                      
survival and proliferation 
Surface glycoconjugates of Leishmania parasites are key determinants in parasite 
survival and virulence in both the insect vector and the mammalian host. The 
promastigote glycocalyx consists mainly of LPG, GPI-anchored glycoproteins and GIPLs 
(Pimenta et al., 1991, McConville et al., 2002, Descoteaux and Turco, 1999) and is 
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indispensable for the parasite survival in the sand fly vector and during the initial steps of 
macrophage infection (Naderer et al., 2004). In contrast the amastigotes lack a 
conspicuous surface glycocalyx. They are coated with a layer of GIPLs and host-derived 
glycosphingolipids (McConville, 1991b). The following paragraph outlines the role of 
promastigote and amastigote surface glycoconjugates. 
 
1.2.2.1 Lipophosphoglycan 
LPG is the predominant cell surface glycoconjugate of Leishmania promastigotes. It is 
clearly essential for parasite survival in the sand fly vector and at least for some species, 
for infectivity in the mammalian host (Sacks and Kamhawi, 2001, Ilg et al., 2001). Initially 
a large number of functions have been attributed to LPG. Recently L. donovani, L. 
mexicana and L. major LPG deficient mutants have been obtained by targeting gene 
deletion of the LPG1 gene and have allowed to reassess many of these functions (Sacks 
et al., 2000, Ilg, 2000a, Späth et al., 2000). LPG1 encodes a putative Golgi 
galactofuranosyltransferase that catalyzes an early step in the synthesis of the LPG 
anchor (Ryan et al., 1993). The targeted gene deletion of LPG1 resulted in complete loss 
of LPG without affecting any other glycoconjugates including the structurally related 
PPGs and GIPLs. Thus these mutants provided excellent tools to rigorously test the roles 
of LPG. LPG roles that have been ascertained are presented below. 
LPG promotes the attachment and detachment from the sand fly midgut. For example, in 
Phlebotomus papatasi, the natural vector of L. major, a lectin recognizing the terminal β-
galactose residues of LPG side chains is responsible for the binding of parasites, 
preventing their excretion with the digested blood meal. The stage specific variations of 
LPG structures described previously are thus essential for the detachment of infectious 
metacyclic parasites and their migration toward the proboscis. In the mammalian host, 
LPG protects the parasite against complement lysis by preventing the insertion of the 
C5b-9 membrane attack complex into the promastigote membrane (Puentes et al., 1990, 
Guha-Niyogi et al., 2001). It can also scavenge oxygen radicals in vitro and seems to 
protect invading promastigotes from the oxidative burst of macrophage generated during 
phagocytosis. Moreover there is strong evidence that LPG inhibits the fusion between 
late endosomal compartments and the newly formed phagosome. Unlike amastigotes, 
promastigotes are vulnerable to degradation by the acidic and hydrolytic environment of 
the phagosome. The delay in phagosome maturation would thus provide a window 
during which promastigotes can differentiate into the more resistant amastigotes. 
However the importance of this delay in phagosome maturation for promastigote survival 
was recently called into question (Murray, 2005). On the other hand, LPG does not seem 
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to be the major surface ligand for macrophage attachment as previously thought. Indeed 
L. major ∆lpg1 mutant was opsonised with C3b to the same extend and was equally 
effective at invading macrophages as wild type promastigotes, although their proliferation 
was clearly reduced in vitro (Späth et al., 2003a). Importantly, mice infection studies with 
L. major ∆lpg1 mutant resulted in delayed lesion formation indicating the importance of 
LPG for the initial establishment of infection (Späth et al., 2000). However, as LPG is not 
expressed by amastigotes, its role is transient and confined to only the early stage of 
infection. The down regulation of LPG even seems indispensable as LPG would 
compromise parasite survival in the host cell (Proudfoot et al., 1996). Interestingly L. 
mexicana LPG is not required for infection of macrophages (Ilg, 2000a). In contrast to 
what is observed in L. major, L. mexicana LPG is not modified nor rearranged during 
metacyclogenesis and LPG expression is dramatically downregulated in the infective 
metacyclic promastigotes. Thus Leishmania species differ dramatically in their reliance 
upon LPG for virulence (Turco et al., 2001). 
 
1.2.2.2 Proteophosphoglycans 
The proteophosphoglycans represent a number of cell surface and secreted proteins, 
which are modified with similar phosphoglycan chains to those found in LPG (Ilg, 2000b). 
The filamentous form of the PPGs, secreted by all Leishmania species, has been shown 
to form a highly viscous mesh within which the parasites lay embedded (Ilg et al., 1996). 
The PPGs block the cardia and the stomodeal valve of the sand fly (Lawyer et al., 1990). 
It has been suggested that the blocking of the digestive tract play a role in the 
transmission of the metacyclic promastigotes (Warburg et al., 1986). Using a L. donovani 
mutant lacking the GDP-mannose transporter gene (LPG2), Descoteaux et al. (1995) 
demonstrated that PPGs are responsible for the protection of the parasite from the 
complement system and proteases in the midgut. The ∆lpg2 mutant that lacks both LPG 
and PPGs is indeed rapidly killed in the sand fly midgut while ∆lpg1 mutant that lacks 
exclusively LPG remained viable during this initial period of infection. Furthermore L. 
major ∆lpg2 is avirulent in a mouse- and macrophage infection model (Späth et al., 
2003b) while the ∆lpg1 mutants lacking exclusively LPG (Sacks et al., 2000) only 
showed a reduced virulence. These result suggested that the PPGs play an important 
role in parasite survival in the mammalian host. PPGs may contribute to the protection 
against complement lysis, to the attachment and invasion of the macrophages (Naderer 
et al., 2004) and may modulate signalling events in the early stages of the infection 
(Guha-Niyogi et al., 2001). The ∆lpg2 mutant is rapidly killed by macrophages and does 
not established lesion in susceptible mice even with relatively high inoculums. 
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Remarkably some viable L.major ∆lpg2 can be recovered from the site of infection 
months after injection. However, this persistence is not sufficient to maintain protective 
immunity (Kebaier et al., 2006). Interestingly, L. mexicana differs again in the mechanism 
of infection, showing no reduced virulence while lacking LPG and PPG (Ilg et al., 2001). 
 
1.2.2.3 GP63 
The glycoprotein 63 (GP63) is a GPI-linked metalloproteinase that is abundantly 
expressed on cell surfaces by all Leishmania species. The protease is believed to 
facilitate survival in the mammalian host. GP63 has been reported to hydrolyse surface 
opsonised complement components (Brittingham et al., 1999), act as a ligand for 
macrophage receptors, either directly or after opsonisation with complement (Alexander 
and Russell, 1992, Joshi et al., 1998), and degrade the extracellular matrix of proteins 
(Joshi et al., 2002). After deletion of the L. major GP63 genomic region (Hilley et al., 
2000), the mutants were 10-fold more sensitive to complement lysis in human serum and 
showed a delayed lesion development in susceptible mice. The amastigotes were as 
virulent as the wild type, indicating that GP63 is not essential for continued survival in the 
mammalian host. As proposed for LPG, there might be a strong selective pressure to 
down-regulate the surface expression of GP63 and other surface proteins with large 
ectopic domains in the amastigote stage as this might be detrimental for amastigote 
survival.  
 
1.2.2.4 GIPLs 
Free GPI or GIPLs are a family of low molecular weight glycolipids that are not attached 
to either proteins or polysaccharides. Because other glycoconjugates are dramatically 
downregulated in the amastigote stage of the parasites, the GIPLs are the predominant 
glycoconjugate in this developmental stage (Naderer et al., 2004). Despite their 
abundance, little is known about the function of these glycolipids. The GIPLs are believed 
to play a role in parasite survival by modulating signaling events. GIPLs are notably able 
to inhibit protein kinase C (an enzyme involved in the first step of the macrophage 
oxidative burst) and nitric oxide production, a compound with leishmanicidal activity 
(Proudfoot at al., 1995, Tachado et al., 1997, McNeely et al., 1989). Recently a 
Leishmania major mutant lacking detectable levels of GIPLs and LPG was generated by 
target gene deletion of a gene encoding the alkyldihydroxyacetonephosphate synthase 
(ADS), a key component in ether lipids biosynthesis (Zufferey et al., 2003). Interestingly 
GPI-anchored proteins like GP63 were still synthesized by this mutant and are thought to 
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be anchored to the membrane via a diacylglycerol. Unexpectedly, the effect on virulence 
of this ∆ads mutant toward mice and macrophages was not stronger than the one 
observed with ∆lpg1. This observation suggests that the GIPLs are not essential for 
infectivity. However the ∆ads mutant expresses an unidentified lipid (Zufferey et al., 
2003) that could have compensated for the loss of these abundant glycolipids.  
 
Throughout their life cycle, Leishmania survive and proliferate in very hostile enviroments 
and have evolved special mechanisms involving the cell surface glycocalyx and secreted 
glycoconjugates that enable them to endure these adverts conditions (Orlandi and Turco, 
1987, McConville and Blackwell, 1991, Ilg et al., 1996). Furthermore various mutants 
deficient in several glycoconjugates nicely demonstrated that the glycocalyx is 
indispensable for parasite virulence toward the insect vector and the mammal host 
(Guha-Niyogi et al., 2001). For example, targeted deletion of the gene encoding dolichol-
phosphate mannose synthase (DPMS) resulted in L. mexicana parasites that lacked all 
GPI-anchored molecules (LPG, GPI-anchored proteins and GIPLs) and had lost 
virulence (Garami and Ilg, 2000). Additionally, parasite surface molecules play an 
important role in the invasion of macrophages. In vivo opsonisation of metacyclic 
promastigotes by C3b and C3bi permits the interaction with macrophage complement 
receptor 1 (CR1) and CR3 respectively. However GP63 converts C3b into C3bi and thus 
favor internalisation via the macrophage complement receptor 3 (CR3), which is 
advantageous to parasite since it will not trigger the oxidative burst during phagocytosis. 
Moreover both GP63 and LPG interact with various macrophages receptors (mannose-
cose receptor, C-reactive protein receptor, fibronectin receptor, CR4). More recently a 
number of surface molecules that play a role during the initial interaction with 
macrophage have been described, although the receptors for these molecules are not 
yet identified. For instance an antibody directed against the terminal β-D-
Galactofuranose residue of GIPLs from either promastigotes or amastigotes inhibited 
internalisation of L. major in vitro (Suzuki et al., 2002).  
Although the initiation of infection is due to the promastigote, the maintenance of 
infection in the mammalian host relies on the amastigotes and their ability to replicate in 
macrophages, and to exit and re-infect new host cells. Less is known about sugars 
mediating interaction of the obligatory intracellular amastigote and its host cells in an 
already established infection (Handman, 2000). For all these reasons, the enzymes 
involved in the biosynthesis of Leishmania cell surface glycoconjugates attract the 
attention of researchers in the hope of defining potential targets that may be exploited 
against leishmaniasis. 
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1.3 Galactofuranose containing glycoconjugates  
1.3.1 Occurrence of Galactofuranose 
The monosaccharide D-galactose occurs naturally in a common pyranic form (a six-
membered carbohydrate ring) and a more unusual furanic form (a five-membered 
carbohydrate ring). D-galactopyranose is widespread and is notably abundant in 
mammalian glycoconjugates. The occurrence of Galactofuranose (Galf) is more 
restricted. It is notably present in structures considered to be essential for virulence of 
pathogenic bacteria, fungi and protozoa but is absent in mammals. In prokaryotes, Galf 
constitutes an essential part of the mycobacterial cell wall (Pan et al., 2001) and occurs 
in lipopolysaccharide O-antigens, extracellular and capsular polysaccharides (Nassau et 
al., 1996, Köplin et al., 1997). In fungi, Galf residues are often found within the cell wall 
polysaccharides and on glycoproteins; e.g., the cell wall galactomannan, some N- and O-
glycans of Aspergillus fumigatus (Latge et al., 1994). Finally, Galf is a key component of 
the abundant protozoan surface GPI-anchored glycoconjugates such as the type 2 
GIPLs and the LPG-anchor of Leishmania or the mucins, GPI-anchored proteins and 
lipids of Trypanosoma cruzi (McConville et al.,1990a, Naderer et al., 2004). Importantly, 
Galf is absent in human and thus the enzymes that are involved in its biosynthesis could 
be attractive targets for development of new antimicrobial drugs (Lederkremer and Colli, 
1995, Pedersen and Turco, 2003). 
 
1.3.2 Galf biosynthetic pathway 
The Galf biosynthetic pathway is simple to describe but has been difficult to unravel. 
UDP- Galf was first shown to be the activated precursor for the synthesis of bacterial and 
fungal polysaccharides (Trejo et al., 1970; Sarvas and Nikaido, 1971) and to originate 
from UDP-galactopyranose (UDP-Galp) (Trejo et al., 1971). In free solution 
galactopyranose (Galp, the common form of galactose) and Galf can interconvert via the 
open chain form of galactose. However, once the reducing oxygen is covalently bonded 
as in UDP-Galactose, the ring is locked. The interconversion of UDP-Galp into UDP- Galf 
requires thus the action of the flavoprotein UDP-galactopyranose mutase (UGM) (Figure 
7). Galf is then transferred from UDP- Galf onto various acceptors by specific 
galactofuranosyltransferases involved in the synthesis of glycoconjugates and 
polysaccharides. To date, very few galactofuranosyltransferases have been identified 
(Huang and Turco, 1993; Kremer et al., 2001; Guan et al., 2001) while UGM has been 
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extensively studied in bacteria because of its key role in Galf metabolism. The gene 
encoding UGM (GLF) has been cloned from a variety of bacterial sources (Nassau et al., 
1996; Weston et al., 1997; Koplin et al., 1997). The crystal structures of E. coli and K. 
pneumoniae UGMs have been solved (Sanders et al., 2001b; Beis et al., 2005) and 
different mechanisms of action proposed (Fullerton et al., 2003; Soltero-Higgin et al., 
2004a). Importantly, targeted gene deletion of UGM affects the cell wall integrity of 
Mycobacterium and results in a lethal phenotype (Pan et al., 2001). As this enzyme 
appears as an attractive target for the development of new antituberculosis drugs, 
assays for inhibitor screens have been developed, and compounds showing activity 
against UGM activity have been identified in prokaryotes (Scherman et al., 2003, Soltero-
Higgin et al., 2004b).  
   
 
 
 
 
 
 
 
Figure 7: UDP-galactopyranose-mutase (UGM) catalyzes the rearrangement of UDP-galactopyranose 
into UDP-galactofuranose. 
 
1.4 Aim of this study 
Does Galf play a critical role in the viability or virulence of Leishmania parasites? 
Leishmania galactofuranosyltransferase LPG1 was the only enzyme of Galf metabolism 
described in eukaryotes (Späth et al., 2000)  until recently (Bakker et al., 2005; Beverley 
et al, 2005). LPG1 was identified by functional complementation of the Leishmania 
donovani R2D2 mutant (Ryan et al., 1993) and was later deleted in L.donovani (Sacks et 
al., 2000), L. mexicana (Ilg, 2000b) and L. major (Späth et al., 2000). These mutants 
were devoid of the abundant cell surface LPG and the remaining LPG core structure 
pointed out to the potential role of LPG1 in Galf transfer. As mentioned previously, the 
targeted gene deletion of this putative galactofuranosyltransferase (LPG1) led to 
attenuated virulence in mice and macrophages and established the role of LPG, and 
therefore Galf metabolism, in oxidant resistance, human complement resistance and 
parasite virulence (Späth et al., 2000). Interestingly the expression of Galf containing 
type 2 GIPLs was not influenced by this gene deletion (Zhang et al., 2003) indicating the 
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existence of a GIPL-specific galactofuranosyltransferase. Because of their abundance in 
the intracellular amastigote stage and their ability to modulate key signaling pathways, 
GIPLs are believed to play important roles in survival of the parasite in and outside the 
macrophages, and are thus suggested to be essential for virulence (Naderer et al., 
2004). Some of the GIPLs functions seem to be associated with their lipid moiety 
(Proudfoot et al., 1996), however, Galf has also been directly implicated in macrophage-
parasite interaction. Indeed an antibody directed against Galf containing GIPLs has been 
shown to inhibit attachment of L. major to macrophages (Suzuki et al., 2002).    
Finally it should be mentioned that Leishmania genome encodes at least 6 putative 
galactofuranosyltransferases homologous to LPG1 whose function are yet undefined 
(Zhang et al., 2004). The gene deletions of three of these LPG1 homologous genes 
showed that they are not involved in LPG or GIPLs synthesis. Thus other leishmanial 
molecules might also contain Galf. Targeting a central enzyme of Galf metabolism such 
as UGM rather than individual galactofuranosyltransferases could thus have a more 
pronounced effect on Leishmania pathogenesis. Our objective was to confirm the 
presumed importance of Galf metabolism for Leishmania major pathogenesis. As Galf is 
absent from human this would validate UGM as target for the development of new 
chemotherapeutic agents against cutaneous leishmaniasis. A mutant deficient in Galf 
was thus generated by targeted gene deletion of GLF, the gene encoding UGM. 
Biochemical characterisation of the mutant confirmed the in vivo role of UGM. Finally the 
virulence of the generated parasites was tested in a mice infection model. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Laboratory animals 
Balb/c mice     Female 8-10 weeks old Balb/c mice were  
      obtained from Charles River laboratories. 
 
2.1.2 Eukaryotic cell line 
L. major MHOM/SU/73/5ASKH: Leishmania major promastigotes cell line, 
kindly provided by Prof. Joachim Clos (BNI 
Hamburg) 
 
2.1.3 Bacterial strains 
E. coli CWG287:   Genotype: (K-12 lacZ trp ∆(sbcB-rfb)upp rel  
rpsL λDE3); Bacteria were kindly provided by  
Chris Whitfield (Canada) 
 
E. coli CWG288:    Genotype: (K-12 lacZ trp ∆(sbcB-rfb)upp rel  
rpsL λDE3 galE:Tn10) ); Bacteria were kindly  
provided by Chris Whitfield (Canada) 
 
E. coli XL-1 blue:    Genotype: recA1 endA1 gyr96 thi-1 hsdR17 
supE44 relA1 lac (Stratagene) [F’proAB 
lacIqZ∆M15 Tn 10 (Tetr)] 
 
E. coli YZ 2000:    Genotype: thr-1 leu-6 thi-1 lacY1 galK2 ara- 
14 xyl-5 mtl-1 proA2 his-4 argE3 str-31 tsx-33 
supE44 recB21, recC22, sbcA23, rpsL31, 
tsx-33, supE44, his-328, mcrA, mcrBC, mrr,  
hsdMRS (Gene Bridges) 
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2.1.4 Phage 
Ffm      The phage Ffm was kindly provided by  
Chris Whitfield (Canada) 
 
2.1.5 Plasmids 
pBluescript II SK(+):  High copy number prokaryotic expression  
vector with ampicillin resistance (Stratagene) 
 
pCR2.1hyg:    Plasmid bearing the hygromycin 
phosphotransferase gene inserted 
between the BspHI and NheI restrictions 
sites of vector pCR2.1 (Invitrogen). This 
plasmid was supplied by Dr. Martin Wiese, 
BNI, Hamburg. 
 
pCR2.1phleo:    Plasmid bearing the phleomycin  
binding protein gene inserted between the 
NcoI and AvrII restrictions sites of vector 
pCR2.1 (Invitrogen) This plasmid was 
supplied by Dr. Martin Wiese, BNI, Hamburg. 
 
pCR4-Topo:    Cloning vector allowing the insertion of DNA 
fragments by TA cloning (Invitrogen) 
 
pET 22 b:    Prokaryotic expression vector for the  
expression of proteins under the control of 
the T7/lac promoter (Novagen).  
 
pET Leis-mut:     Plasmid for expression of L. major UDP- 
galactopyranose mutase in prokaryotes. 
UGM was amplified from genomic DNA using 
the primer pair HB1/HB2 and inserted 
between the restriction sites NdeI/XhoI of 
pET-22b (Novagen). 
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pWQ66:     Expression vector carrying the the glfKPO1  
gene of Klebsiella pneumoniae 
provided by Chris Whitfield (Canada) 
 
pWQ70:     Expression vector carrying the O-antigen  
cluster of Klebsiella pneumoniae and an in-  
frame deletion in the glfKPO1 gene (UGM),  
provided by Chris Whitfield (Canada) 
        
pXG:      Leishmania expression vector with neomycin  
resistance was kindly provided by Stephan 
M. Beverley (St. Louis, USA).  
(Map as appendice) 
 
pXG-GLF:     Construct for episomal expression of UGM in  
Leishmania. GLF was amplified with the 
primer pair BK22/BK18 and cloned via 
SmaI/BamHI in pXG. 
 
pXG-LMSAP1:    Construct for episomal expression of L.  
mexicana secreted acid phosphatase that  
was kindly provided by Stephan M. Beverley  
(St. Louis, USA). 
 
pXG-GFP:   Leishmania vector containing a modified GFP 
was kindly provided by Stephan M. Beverley  
(St. Louis, USA). (Map as appendice) 
 
pXG-GFP+2:    Leishmania vector for N-terminal  
GFP labelling of proteins was kindly provided 
by Stephan M. Beverley (St. Louis, USA). 
(Map as appendice) 
 
pXG-GFP+2UGM:  Construct for UGM localisation. GLF lacking  
the start codon was amplified with the primer  
pair BK17/BK18 and cloned in the sense  
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orientation in the BamHI site of pXG-GFP+2. 
 
P5’UTR-Topo:    Construct bearing the 5’ flanking region of L.  
major GLF. The fragment was amplified from  
genomic DNA with the primer pair 
BK13/BK14 and inserted into pCR4-Topo. 
 
3’pBSK +:     Construct bearing the 3’ flanking region of L.  
major GLF. The fragment was amplified from  
genomic DNA using the primer pair FR3/FR4  
and inserted via the SacI and XbaI  
restrictions sites of pBluescript II SK(+). 
 
3’5’pBSK +:   Construct bearing 3’ and 5´ flanking region of  
L. major GLF . The 5’UTR from genomic  
DNA was amplified with the primer pair  
FR1/FR2 and inserted into the XhoI/BamHI  
sites of 3’pBSK +. 
 
P3’5’phleo:    Construct for targeted gene replacement of 
GLF. Plasmid bearing the phleomycin 
resistance marker flanked by the 5’ and 3’ 
untranslated regions of L. major GLF. The 
phleomycin resistant marker was amplified by 
the primer pair BK7/BK8 from pCR2.1phleo 
and inserted between 5’ and 3’ UTR of GLF 
in 3’5’pBSK + by homologous recombination 
in YZ 2000. 
 
P3’5’hyg:     Construct for target gene replacement of 
GLF. Plasmid bearing the hygromycin 
resistance marker flanked by the 5’ and 3’ 
untranslated region of L. major GLF. The 
hygromycin resistant marker was amplified 
by the primer pair FR6/FR7 from pCR2.1hyg 
and inserted between 5’ and 3’ UTR of GLF 
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in 3’5’pBSK + by homologous recombination 
in YZ 2000. 
 
2.1.6 Oligonucleotides 
All oligonucleotides were purchased from MWG. 
 
Sequencing primers for L. major GLF (5’ ➠ 3’) 
 
BK10    GCGTAGCGGGAGAAGATC 
BK11    TGATCCCAGAGGCGCACA 
BK26    TTCACCTTGGTTACGCGGCA 
BK27    AGGCCGTGTGGAAGATGATC 
BK28    GCCTCGACGCCCTGCATC 
BK29    CTATTCACGCGGCCGCTTC 
 
Sequencing primers for L. major GLF flanking regions (5’ ➠ 3’) 
 
FR9    TCTCACGCCTCACTTCTAAG 
FR10    CCATGGTGAAGGTCGTCGT 
FR11    ACCATAGGCGTCGACGATGA 
FR12    TGCTTCAATTTCGCACGTCT 
 
Primers for homologous recombination control (5’ ➠ 3’) 
 
ACM99   GACGTCGCGGTGAGTTCAGG  
ACM100   GTCCGAGGGCAAAGGAATAG 
ACM101   GAACGGCACTGGTCAACTTGG 
ACM102   GTGGCCGAGGAGCAGGACTG 
BK9    TGTGCAGGAGGGGTGGAA 
BK12    ATCGGAGAACACGGCCTG 
 
Sequencing primers for plasmids (5’ ➠ 3’) 
 
ACM85   ATGAAAAAGCCTGAACTCACCG 
ACM86   CTATTCCTTTGCCCTCGGAC 
ACM87   ATGGCCAAGTTGACCAGTGC 
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ACM88   TCAGTCCTGCTCCTCGGCC 
BK19    CTGCTGGAGTTCGTGACCG 
BK30    AGGGCATGATAGTCCGCTCT 
BK31    ATAGTCCGCTCTTGAGGGCA 
T7    TAATACGACTCACTATA 
T7term   GCTAGTTATTTGCTCAGCGG 
 
PCR amplification primers (5’ ➠ 3’) 
 
BK7    CATCAACTGACGCAACGCAGGCACACGCAGCA 
AATCCATCATGGCCAAGTTGACCAGTGCC 
BK8    CTCCCTCGTCCTCCTCGTCCATGGCTGCCGACC 
    TTGGCCTTCAGTCCTGCTCCTCGGCCAC 
BK13    TTATCGTGTACTTCATTTGCTCG 
BK14    TTCCACCCCTCCTGCACACT 
BK17    GTCTGGATCCAGCGCTGACAAGGTGGTCATA 
BK18    GCCTGGGATCCTACGAGGCCGTCGACGAC 
BK25    GTCTGGATCCATGAGCGCTGACAAGGTGGT 
FR1    CAAACTTCTTCGAGGCTATCAAG 
FR2    GTCTGGATCCATGATGGATTTGCTGCGTGTG 
FR3    CAAGTCTAGAGGCCAAGGTCGGCAGCCA 
FR4    GCCTGGAGCTCAAACTCCGCCAAAAC 
FR6    GACGCAACGCAGGCACACGCAGCAAATCCATC 
ATGAAAAAGCCTGAACTCAC 
FR7    TCCTCCTCGTCCATGGCTGCCGACCTTGGCCTC 
TATTCCTTTGCCCTCGGAC 
HB1    GCAAATCCATATGAGCGCTGACAAGGTG 
HB2    TCGCTCGAGCATGTGCAGCGCATCTCACC 
 
2.1.7 Antibodies 
2.1.7.1 Primary antibodies 
GP63-235: monoclonal antibody (mouse IgG1) directed against GP63 
(hybridoma culture supernatant was generously provided by W. 
Robert McMaster ,Vancouver, Canada).  
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L-5-28: monoclonal antibody (mouse IgG1) reacting with GIPL2 and 
GIPL3 (purified antibody was generously provided by E. 
Handman, Victoria, Australia) 
 
L-5-34: monoclonal antibody (mouse IgG1) reacting with GIPL2 and 
GIPL3 (purified antibody was generously provided by E. 
Handman, Victoria, Australia) 
 
LT8.2: monoclonal antibody (mouse IgG1) directed against linear peptide 
epitope of Leishmania mexicana SAP (hybridoma culture 
supernatant was supplied by Martin Wiese) 
 
MEST1: monoclonal antibody (mouse IgG1) directed against terminal 
galactofuranose of GIPL 1 (lyophilized hybridoma culture 
supernatant was generously provided by AH Straus, Sao Paulo, 
Brasil) 
  
WIC79.3: monoclonal antibody (mouse IgG1) directed against galactose 
substituted repeating unit of LPG (ascites fluid supplied by Martin 
Wiese) 
 
2.1.7.2 Secondary antibodies, sera and conjugates 
Anti-mouse-IgG Cy3 conjugate     Sigma 
Anti-Digoxigenin Fab AP conjugate     Roche 
Anti-mouse-Ig AP conjugate      Dianova 
Anti-mouse-Ig HRP conjugate     Dianova 
DAPI         Sigma 
 
2.1.8 Molecular weight markers 
‘1 kb DNA ladder’        Invitrogen 
‘SDS-PAGE molecular weight standards high range’   BioRad 
‘Prestained Precision Protein Standards’     BioRad 
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2.1.9  Enzymes 
Alkaline calf intestine phosphatase New England Biolabs  
cloned Pfu-DNA-Polymerase  Stratagene 
Lysozyme Serva 
Proteinase K Boehringer- Mannheim 
Restriction enzymes  New England Biolabs 
T4-DNA-Ligase  New England Biolabs  
Taq-DNA-Polymerase  Sigma 
 
 
2.1.10 Culture media and additives 
 
Adenin Sigma 
Ampicillin, sodium salt Serva 
Carbenicillin, disodium salt Fluka 
Fetal calf serum Invitrogen 
Hemin Fluka 
Hygromycin B Sigma 
Kanamycin Sigma 
LB-agar Becton Dickinson 
LB-medium  Becton Dickinson 
M199 powder GibcoBRL 
Noble agar Becton Dickinson 
paraformaldehyde Sigma 
Penicillin/Streptomycin Sigma 
Phleomycin Sigma 
Poly (L)-lysine Sigma 
RPMI 1640 medium Gibco 
Terrific Broth medium Sigma 
RotiTMPhenol Roth 
 
2.1.11 Kits and further materials 
 
CarboPac PA- 10 colum, 2x 250mm DIONEX 
Cell culture bottles and dishes Sarstedt 
Cellulose acetate filter (0,22µm, 0,8 µm) Sartorius 
Electroporation cuvettes BioRad 
Filter paper  Whatman 
Glas capillaries Macherey-Nagel 
Glas tubes with Teflon cap DIONEX 
Hyperfilm MP Amersham Biosciences 
HPTLC-plates Nano-DURASIL-20 size 10 x 10 cm  Macherey-Nagel 
Microtiter plates 96-well polystyrol (U-bottom) Greiner 
Nitrocellulose membrane (0,45 µm) Schleicher & Schuell 
Nylon membrane (Hybond-N+) Amersham Biosciences 
PCR-tubes (0,2 ml) Biozym 
Plastic disposable pipettes (5 ml, 10 ml, 25 ml) Sarstedt 
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Polypropylen tubes (14 ml, 50 ml) Greiner 
QIAGEN Plasmid Mini und Midi Kit Qiagen 
Qiaquick Gel Extraction Kit Qiagen 
Qiaquick PCR purification kit Qiagen 
Reaction tubes (0.5 ml, 1.5 ml) Sarstedt 
Reaction tubes safelock (1.5 ml, 2 ml) Eppendorf 
Sterile filters Millex GP (0,22 µM) Milipore 
Syringes (2 ml) Braun 
 
2.1.12 Standard buffer and media 
 
20xSSC 3 M NaCl 
0.3 M Sodium citrate pH 7.0 
2xLaemmli 200 mM Tris-HCl pH 6.8 
30% (v/v) glycerol 
3% (w/v) SDS 
0.1% (w/v) bromophenol Blue 
5% (v/v) 2-mercaptoethanol 
5xGEBS 20% glycerol 
50 mM EDTA 
0.05% bromophenol Blue  
0.5% sarcosyl 
5xLaemmli 600 mM Tris-HCl pH 6.8 
40% (v/v) glycerol 
10% (w/v) SDS 
0.4% (w/v) bromophenol Blue 
5% (v/v) 2-mercaptoethanol 
AP-buffer 100 mM Tris-HCl pH 9.5  
100 mM NaCl 
5 mM MgCl2 
BCIP 25 mg/ml BCIP in 100% DMF 
ECL-reagent 125 mM Luminol 
45 mM p-Cumaric acid 
1M Tris/HCl pH 8.5 
15% H2O2 
NBT 50 mg/ml NBT in 70% (v/v) DMF 
PBS 10 mM sodium phosphate pH 7.4 
150 mM NaCl 
PBS/EDTA 10 mM sodium phosphate, pH 7.4 
150 mM NaCl 
2 mM EDTA 
SOB (SOC) 2% bactotryptone  
0.5% yeast extract  
10 mM NaCl 
2.5 mM KCl 
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10 mM MgCl2 
10 mM MgSO4 
(2% glucose) 
 
TAE 40 mM Tris-Acetate 
2 mM EDTA 
pH 8.5 
TBE 100 mM Tris-HCl, pH 8.0 
100 mM Borate 
2.5 mM EDTA 
TELT 50 mM Tris-HCl, pH 8.0 
62,5 mM EDTA pH 9.0 
2,5 M LiCl 
4% (v/v) Triton x-100 
TBS 20 mM Tris-HCl, pH 7.4 
150mM NaCL 
 
TE  10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
2.1.13 Chemicals 
 
ABTS  Roche 
Acetic acid (100 %) Merck 
Aceton Baker 
Acrylamide 40% 4 K-Mix (37.5:1) Serva 
AEC Sigma 
Agarose Serva 
Ammonium chloride  Merck 
Ammonium persulfate (APS) Serva 
BCA Protein Assay Reagent  Pierce  
BCIP (5-Bromo-4-chloro-3-indolyl-phosphate) Fluka 
Beta-Mercaptoethanol Sigma 
Borate, sodium salt Merck 
Bromophenol Blue, sodium salt Applichem 
BSA (Fraktion V) Applichem 
BSA protein standard Pierce 
Chloroform Baker 
Citric acid Merck 
CSPD Roche 
Dimethylsulfoxide (DMSO) Merck 
Dipotassium hydrogen phosphate Merck 
Disodium hydrogen phosphate  Merck 
Disodium hydrogen phosphate Merck 
Dithiothreitol (DTT) Sigma 
dNTPs (100 mM each) Pharmacia 
Dry milk Applichem 
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EDTA, Disodium salt (Titriplex III) Merck 
Ethanol, absolut Baker 
Ethidium Bromide USB Corporation 
Formaldehyde Sigma 
Glycerin (99%) KMF 
Glycine Sigma 
Hydrochloric acid (38%) Baker 
Hydrogen peroxide Fluka 
Imidazole Fluka 
Isopropanol (2-Propanol) Merck 
Korsolex plus Roche 
Methanol Baker 
Methanolic- HCL (0.5N) Supelco 
Moviol Baker 
NBT (Nitrotetrazolium bluechloride) Fluka 
Pepstatin Roche 
Phenylmethylsulfonyl fluorid (PMSF) Sigma 
Polyisobutylmethacrylat Sigma 
Ponceau S, sodium salt Sigma 
Potassium dihydrogen phosphate Merck 
Potassium chloride Applichem 
Roti-Blue Coomassie-stain (5x) Roth 
Saponin Sigma 
Sodium acetate Merck 
Sodium chloride Merck 
Sodium dihydrogen phosphate  Merck 
Sodium dodecylsulphate (SDS) Merck 
Sodium hydroxide Merck 
Sodium periodate  Sigma 
TEMED (N,N,N’,N’-Tetramethyl-ethylendiamin) Serva 
TRIS (Tris(hydroxymethyl)-aminomethan) Merck 
Tween-20 Fluka 
 
 
All chemicals not explicitly listed above were purchased in p.a. quality from either Merck 
or Sigma. 
 
2.1.14 Laboratory Equipment 
 
Blotting chamber  Fast-Blot B44 Biometra 
Centrifuges :  - Biofuge fresco  
 - Biofuge pico  
 - Multifuge 3 S-R 
 - Centrifuge 5415C 
 - Coulter Avanti J-30I 
Rotors: - JA 25.50 
 - JLA 10.500 
 - JS-24.15 
Heraeus  
Heraeus 
Heraeus 
Eppendorf 
Beckman 
Beckman 
Beckman 
Beckman 
Easy Enhanced Analysis System  
(E.A.S.Y RH-3, Videocamera 429K) 
Herolab 
Electroporator BioRad 
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Electrophoresis chamber for agarose-gels peqlab 
Electrophoresis chamber for SDS-PAGE BioMetra 
ELISA-Reader: DigiScan Asys Hitech 
Heatingblock TB1 BioMetra 
HeraSafe Hood Heraeus 
High pH Anion Exchange chromatograph DIONEX BioLC 
Incubators Heraeus 
Peristaltic pump P-1 Amersham Biosciences 
Scales CP 224S (µg) / CP 3202 (g) Sartorius 
Sonifier 450 Branson 
Spectrophotometer Ultrospec 2100 pro Amersham Biosciences 
Speedvac RVC 2-18 Christ 
Standard Power Pack P25 Biometra 
Stratalinker Stratagene 
Thermocycler T1 and T Gradient Biometra 
Thermomixer compact Eppendorf 
ULTRAFLEX™ MALDI-TOF/TOF spectrometer Bruker 
           
2.2 Cell biological approach 
2.2.1 Leishmania major culture conditions 
 
Promastigotes of L. major MHOM/SU/73/5ASKH were grown at 27°C in M199 medium 
supplemented with 10% fetal bovine serum, 40mM Hepes pH 7.5, 0.1mM adenine, 
0.0005% hemin, 0.0002% biotin and 50 U/ml penicillin/streptomycin. As needed, G418, 
hygromycin B and phleomycin were added at 30, 50 and 5 µg/ml respectively. The 10 ml 
cultures were passaged every 3-4 days at a dilution from 1:50. The saturation density of 
this L. major strain ranged from 4-5 x107 cells/ml. Selection of individual clones after 
transfection was done on semi-solid M199 medium containing additionally 1% noble 
agar.  
For long time storage, 4x107 cells were pelleted, resuspended in 1,5 ml FCS 
supplemented with 10% DMSO and transferred into cryo-tubes. Cells were slowly frozen 
in the gas phase of the liquid nitrogen tank or in the -80°C fridge over night. The next day 
tubes were transferred into liquid nitrogen. To revive L. major culture, an aliquot was 
thawed in a water bath at 37°C and transferred to 10 ml fresh M199 media containing the 
appropriate antibiotics. 
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2.2.2 In vitro growth 
For analyzation of the in vitro growth of the Leishmania parasites fresh 10 ml M199 
media, containing the appropriate antibiotics, was inoculated with  5, 5 x 106 parasites. 
The cultures were counted every 24 h for 5 days in duplicate using a light microscope. 
 
2.2.3 Electroporation conditions for L. major 
The protocols for target gene replacement in L.major were kindly provided by Prof. Jon 
LeBowitz (Purdue University, West Lafayette, USA) and combined with an improved 
transfection protocol according to Robinson et al., (2003). Parasites were grown to a 
density of approximately 107 cells/ml and 1-2x108 parasites were harvested by 
centrifugation at 1300 xg for 10 min at 4°C. Parasites were washed once in 
electroporation buffer (21 mM Hepes, pH 7.5, 137 mM NaCl, 5 mM KCl, 0.7 mM 
NaHPO4, 6 mM glucose), resuspended in 500 µl electroporation buffer and mix with 2 µg 
linearised targeted gene replacement construct bearing a resistant marker or 10 µg of the 
appropriate plasmid in a 4 mm cuvette. The cells were electroporated by two pulses at 
25µF and 1.5 kV, incubated on ice for 10 min, transferred into 10 ml M199 media and left 
at 27 °C for 24 h. The culture was then centrifuged at 1300 xg for 10 min at 20°C, 
resuspended in 100 µl culture media and transferred on M199 agar plates (2x M199 
culture media combined with an equal volume of 2% noble agar) containing the 
appropriate antibiotics. The M199 agar plates were protected from dehydration by 
wrapping them with parafilm and were incubated upright in the incubator at 27°C.  After 
two weeks the colonies on the plates became visible and were transferred and expanded 
in 10 ml M199 media containing the appropriate antibiotics. 
 
2.2.4 Fluorescence and Immunofluorescence microscopy 
Leishmania parasites were analysed by immunofluorescence using the monoclonal 
antibodies WIC 79.3 or GP63-235. The cells were immobilised on 10-well glass 
coverslips coated with poly(L)-lysine (0.1 mg/ml in PBS). 500 µl parasites from a 2 x 107 
cells/ml dense culture were harvested, washed once in PBS and resuspended in 500 µl 
PBS. 20 µl cells were transferred with the same amount of 4% PFA in each well and 
incubated for 20 min at room temperature. The cells were washed twice with PBS and 
permeabilized with 50 mM NH4Cl for 15 min. Incubation with 2% BSA in PBS for at least 
15 min was used to prevent unspecific absorption of antibodies.  This solution was kept 
in subsequent incubation with the primary antibody (WIC 79.3 mAb ascites fluid 1:1000 
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or GP63-235 mAB hybdridoma culture supernatant 1:10). After 1 h, cells were washed 4 
times with PBS and incubated for 30 min in the dark with a mixture of secondary antibody 
goat α−mouse Cy3 1:500 and 8µg/ml DAPI in 2% BSA/PBS. After five washing steps 
with PBS the slides were embedded in Mowiol and inspected with the 40 x and 100 x 
magnification of a fluorescence microscope.  
Similar procedure was used for localisation experiments using a GFP tagged GLF 
construct. Parasites were immobilised to poly-L-lysine coated coverslips and fixed in 4% 
paraformaldehyde in PBS for 20 min at room temperature. Additionally the cells were 
stained with 8µg/ml DAPI for 30 min in the dark before embedding in Mowiol and 
inspection by fluorescence microscopy at a 100 x magnification.  
 
2.2.5 Mice infection model 
Because Leishmania tend to lose virulence in culture the parasites were passaged once 
through mice. Parasites were grown to late logarithmic phase and 107 parasites per 
mouse were injected in the hind left footpad. After 10 days the parasites were re-
extracted from lymph nodes and transferred to liquid media at 27 °C, to allow the 
transformation of the parasites from amastigote to promastigote. The reisolated parasites 
were expanded and DMSO stocks were prepared. These cultures were passaged less 
than three times. For the mice infection studies the parasites were grown to late 
logarithmic phase. 2 x 106 parasites were harvested at 1300 xg for 10 min at 4°C. The 
cell pellet was resuspended in 100 µl PBS and immediately injected into the left hind 
footpad of a Balb/c mouse (Charles River). The infection was controlled once a week by 
determining the infected and non infected footpad with a Vernier calliper. The median 
size difference of the infected and non infected footpad was monitored for 11 weeks after 
post infection. 
 
2.3 Biochemical techniques 
2.3.1 Assignation of protein concentration  
Protein concentration was determined using the ‘BCA Protein Assay Reagent’ (Pierce) 
following the manufacturers instructions. Shortly the reagents A and B were mixed in a 
ratio of 50:1 before use. 200 µl of the mixture were mixed with 10 µl of sample in a 96-
well microtiter plate. For reference a dilution series of 25-200 µg/ml BSA was included. 
The plate was incubated for 30 min at 55°C and absorbance was measured at 540 nm in 
                                                                                             Materials and Methods 
 34
the ELISA-Reader ‘DigiScan’ (Asys Hitech). The protein concentration of the samples 
was calculated from the BSA standard curve. 
 
2.3.2 Activity assays of UGM  
2.3.2.1 In vivo activity assay of UGM 
The activity of UGM of Leishmania major was analysed by an in vivo complementation of 
E. coli CWG287 lacking a functional UGM. The open reading frame of Leishmania major 
was amplified by PCR using the primer pairs HB1/HB2 and cloned via NdeI/XhoI into 
pET22b, resulting in pET-Leis-mut. The plasmid pWQ70 containing the O-antigen gene 
cluster from Klebsiella pneumoniae KPO1 with a deletion in the UDP-galactopyranose 
mutase gene (glfKPO1) was transformed into E.coli CWG287. Chemically competent cells 
were prepared with these bacteria and transformed with a second plasmid containing 
either GlfKPO1 (pWQ66), the candidate gene of Leishmania major (pET Leis-mut) or empty 
pET22b vector. The transformants were grown in LB media with antibiotics for 10 hours. 
Antibiotics were added to 5 ml LB maintained at 50oC and mixed with 1 ml fresh bacterial 
culture and immediately plated. Bacteria were allowed to grow for 2 H after which 5 µl 
drops containing 106 (top left), 105 (top right), 104 (bottom left) and 103 pfu/ml of phage 
Ffm were deposit on each plate. The plates were incubated at 37°C for 10h.  
Protein-free LPS preparations were obtained by the SDS-proteinase K lysate method. 
Freshly transformed bacteria were harvested from an agar plate with PBS (pH 7,2) and 
the OD adjusted to 0.4. Bacteria from 1.5ml suspension were pelleted and solubilized in 
50 µl of lysing buffer containing 2% SDS, 4% 2- mercaptoethanol, 10% glycerol, 0.1 M 
Tris-HCl (pH 6,8) and bromphenol blue. The lysated were heated at 100°C for 10 min.- 
For protein digestion, 25 µg of proteinase K was solubilized in 10 µl of lysing buffer was 
added to each boiled lysate an incubated at 60°C for 60 min. Protein-free LPS 
preparations obtained by the SDS-proteinase K lysate method were analyzed by SDS-
PAGE (2.3.9) and silver-stained (2.3.11). 
 
2.3.2.2  In vitro activity assay of UGM 
Plasmid containing either glfKPO1or the potential GLF gene of L. major (pET-Leis-mut) 
was transformed into E.coli CWG288. Transformants were then grown in terrific broth 
with antibiotic until OD600 0.6 and induced with 0.4mM IPTG for 3H at 30oC. Cells were 
collected by centrifugation, washed with ice cold buffer and resuspended at an OD600 10 
in 50mM Hepes pH 7.4, 1mM PMSF; 1mM DTT. Cells were then treated with lysozyme 
(100µg/ml) at room temperature for 30min and lysed by sonication using a Branson 450 
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sonifier. Cell debris was removed by centrifugation at 16000G for 30min at 4oC. Protein 
concentration of the supernatant was determined using the BCA assay (Pierce). The 
assay was based on the method developed by Scherman et al. (2003) using UDP-[6-
3H]Galp purchased from Amersham. Briefly, 0.5µg of crude protein extract were 
incubated with 100µM radioactive UDP-Galp (specific activity: 75 Bq/pmol) in 25µl buffer 
containing 25mM Hepes pH 7.2, 1mM MgCl2 and 1mM NADH for 20min at 37oC. 
Nucleotides were then oxidized by NaIO4 (200 mM) and the reaction was stopped by the 
addition of 3µl of ethylene glycol. After dilution with 100µl H2O, products were loaded on 
a 300µl column of AG 1X8 (200-400 mesh; acetate form) (Biorad) and the column was 
washed with 100µl H2O. After addition of 2ml of Lumasafe Plus scintillation cocktail 
(Lumac, The Netherlands) to the efluent, radioactivity was counted. 
 
2.3.3 Preparation of total cell lysates for GP63 and LPG analysis 
For analysis of GP63, LPG and PPG, 1x108 parasites were centrifuged at 1300 xg for 10 
min and washed two times with cold PBS. The cells were resuspended in 100 µl lysis 
buffer (50 mM Tris/HCl pH 8,0, 0,1% Triton X-100, 1 mM PMSF, 2 µg/ml Leupep-tin, 5 
µg/ml Pepstatin) and disrupted by sonification in a beaker resonator 4 times for 30 
seconds (Branson, 100% Duty cycle, output control 5, 4°C). Disruption was checked 
under a light microscope. Cell debris were removed by centrifugation at 13000xg for 10 
min at 4°C.  2 x Laemmli buffer was added to an aliquot of the lysate, and 12,5 µg protein 
per sample were loaded on a 8% ProSieve gel (2.3.9). 
 
2.3.4 Preparation of lysates for GIPLs analysis 
4 x 108 parasites were pelleted at 1300xg for 10 min and washed to times in cold PBS.  
The cell pellet was resuspended in 500 µl Chloroform/Methanol/Water ratio of 1:2:0,8. 
The cells were sonified in a beaker resonator 5 times for 30 seconds (Branson, 100% 
Duty cycle, output control 5, 4°C). Cell debris was removed by centrifugation at 13000 xg 
for 10 min at 4°C. The supernatant were kept and the cell pellet was reextracted with 500 
µl Chloroform/Methanol/Water ratio of 1:2:0,8 following by sonification and centrifugation. 
The combined supernatants were evaporated to dryness under a stream of nitrogen, 
resuspended in water and purified over a C18/SepPak® Plus column (Waters). GIPLs 
were eluted in methanol, dried under a stream of nitrogen, resuspended in Chloroform/ 
Methanol/ Water (30:60:8) and analysed by mass spectrometry. 
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2.3.5 HPTLC analysis 
After extraction of GIPLs (2.3.4) the samples were resuspend in 15µl Chloroform: 
Methanol:0.2% KCL (10:10:3 v/v). 150ml Chloroform:Methanol:0,2% KCL (10:10:3 v/v) 
were added to a glass chromatophy tank (25cm x 27cm x 10cm) lined with filter paper 
(ca. 17cm x 19cm) and covered tightly. The vapors in the tank were equilibrated for at 
least 2h. The Glycolipids were spotted on the HPTLC plate using a glass capillary. The 
plate was placed in the tank with the samples just above the level of solvent. The tank 
was covered tightly and the plate was left until the ascending solvent line reached the top 
of the plate. The TLC plate was dried under the hood for 10 min. The plates were 
incubated 2 h with the primary antibodies (L-5-28 (1:40), L-5-34 (1:200) and MEST1(1:5)) 
in BSA/TBS. The plates were washed three times for 5 min with TBS and incubated with 
α-mouse Ig coupled to AP antibody (1:2000) in BSA/TBS. The plates were rinsed three 
times with TBS and once with AP buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 5 mM 
MgCl2). The visualization of the glycolipids was achieved by incubation with the substrate 
BCIP/NBT (0.3 mg/ml NBT, 0.15 mg/ml BCIP in AP-buffer). The reaction was stopped by 
the addition of water.  
 
2.3.6 Matrix assistance laser desorption (MALDI) mass spectrometry 
The GIPLs were further analysed by mass spectrometry using 6-Aza-2-thiothymidine 
(5µg/µl) as matrix. 1 µl of the matrix was added and fixed on a high grade steel plate 
under a stream of hot air. 5 µl of the GIPLs extracts (2.3.4) was layered on the matrix by 
hot air drying.  Finally 1 µl of the matrix was coated on top. Mass spectra were recorded 
on a Bruker ULTRAFLEX™ MALDI-TOF/TOF spectrometer in the negative mode and the 
instrument was used at a maximum accelerating potential of 20 kV. The data were 
analysed with the Bruker flexAnalysis 2.0 program.  
 
2.3.7 HPAEC analysis  
The GIPLs were investigated by High pH Anion Exchange chromatography (HPAEC). 
GIPLs from 4 x 108 Leishmania promastigotes were extracted (2.3.4) and evaporated to 
dryness in a glass tube with teflon cap. Methanolysis of glycosides was performed by 
addition of 150 µl 5mM methanolic-HCL (prepared by diluting 0.5N methanolic-HCL with 
anhydrous methanol) and incubation at 84°C for 3h.  The samples were evaporated 
under a stream of nitrogen at room temperature. 50µl butanol were added and the 
samples dried again. This step was repeated 3 times. The samples were dissolved in 
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100 µl H2O, injected on an analytical CarboPac PA-10 (2 x 250 mm) column and eluted 
isocratically in NaOH (18mM) at a flow rate of 0,25ml/min. The data were analysed with 
the DIONEX Chromeleon software.  
 
2.3.8 Immunoprecipitation 
For immunoprecipitations of the L. mexicana secreted acid phosphatase, 1 ml cell culture 
supernatant was incubated with purified LT8.2 monoclonal antibody for 1h at 4°C. 50 µl 
of a 50% slurry Protein-A sepharose beads (Sigma) were added and after 1h at 4°C, the 
samples were centrifuged at 500 x g for 30 seconds. The supernatant was removed and 
the beads washed four times with 1 ml 50 mM Tris/HCl, pH 8.0, 0.5% NP-40. The 
samples were resuspended in 20 µl 2x Laemmli buffer, boiled at 95°C for 5 min and 
separated on a SDS PAGE. 
 
2.3.9 SDS-PAGE 
The SDS-polyacrylamide gels were performed according to Laemmli (Laemmli, 1970). 
The protein samples were separated on SDS-polyacrylamide gels consisting of a 
5 % stacking gel (125 mM Tris/HCl pH 6.8, 0.1 % SDS, 5 % polyacrylamide) and a 10 % 
separating gel (375 mM Tris/HCl pH 8.8, 0.1 % SDS, 7-14 % polyacrylamide) or 8% 
ProSieve® 50 (gel solution, Cambrex) gradient gel. For the gel preparation the buffer, 
SDS and the acrylamide stock solution were mixed (37.5 % acrylamide, 1 % 
bisacrylamide or ProSieve) and polymerisation was initiated by adding 0.1 % TEMED 
and 1 % ammonium persulfate. 2x or 5x Laemmli-buffer was added to the protein 
samples and heated to 95 °C for 5 min.  Electrophoresis was performed in SDS-
electrophoresis buffer (50 mM Tris, 350 mM glycine, 0.1 % SDS) at 15 mA (stacking gel) 
and 20 mA (separating gel) per gel.   
 
2.3.10 Coomassie staining of SDS gels 
The Roti®-Blue (Roth) staining solution was used for the protein gels staining. 
Immediately after electrophoresis (2.3.9) the gels were incubated in 20 ml 1xRoti®-Blue in 
20 % methanol over night. The gels were destained in 20 % ethanol containing 10 % 
glycerol and dried.  
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2.3.11 LPS Silver staining  
The SDS gels were soaked overnight in 40% isopropanol and 5% acetic acid in 200 ml of 
distilled water. The gels were incubated for 5 min in periodic acid solution (0.7% periodic 
acid 40% ethanol 5% acetic acid) to oxidise the LPS and rinsed in running destilled water 
for 2 h.  The gel was stained for 10 min with freshly prepared staining solution which was 
prepared as follows. A 2 ml volume of concentrated ammonium hydroxide was added to 
28 ml of 0.1 N  sodium hydroxide. After the addition of about 115 ml of water, 5 ml of 
20% silver nitrate was added in drops with stirring. The gel was washed three times in 
deionised water for 15 min and incubated afterwards in freshly prepared developer 
solution containing 10 mg citric acid and 0,1 ml  30% formaldehyde in 200 ml of water 
until bands were lighting up. The color reaction was stopped and fixed by exposure to 
0.35% acetic acid for one hour. The gels were destained in drying buffer (20 % ethanol, 
10 % glycerol) and dried after 3-4 hours.  
 
2.3.12 Western Blot 
After the electrophoresis the protein samples on the SDS page were transferred to 
Hybond nitrocellulose membranes (Amersham, Bioscience) using a semidry blotting 
chamber (Biometra) at 2 mA/cm2 for 1 h.  Gel and membrane were placed in between 
two layers of Whatman filter papers soaked in blotting buffer (48 mM Tris, 39 mM 
glycine). Transfer efficiency was checked by labeling with Ponceau S-solution (0.2 % 
(w/v) Ponceau S in 3 % TCA) and destained in deionised water and PBS. 
 
2.3.13 Immunostaining of Western Blots 
After western blotting (2.3.12) the membrane was blocked over night in blocking buffer 
consisting of 2% BSA/PBST (2% BSA, PBS, 0,1 % Tween). After three times washing of 
10 min in PBST (PBS, 0,1% Tween), the membrane was incubated for at least 1 h with 
the first antibody in 2% BSA/PBST (WIC 79.3 mAb ascites fluid 1:4000; GP63-235 
hybridoma supernatant 1:50). The blots were washed in PBST (PBS, 0,1% Tween) three 
times for 10 min and two times for 15 min. Finally the blots were incubated with α−mouse 
Ig coupled to HRP at 1:50 000 in 2% BSA/PBST, 0,1% Tween for 1 hour at room 
temperature. The membranes were washed 3 times for 10 min and two times for 15 min 
in TBST (0,1 % Tween). To detect the signals an ECL detection system was used. The 
ECL detection solution was prepared by mixing a Luminol  solution (250 mM Luminol, 90 
mM p-Cumaric acid, 1 M Tris/HCl, pH 8.5) with a hydrogen peroxide  solution (1 M 
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Tris/HCl, pH 8.5, 30% H2O2) in a 1:1 ratio. After 15 min of incubation, the ECL solution 
was removed from the membrane. The blot was wrapped in a plastic sheet and the 
signals exposed for 1-10 min to a Hyperfilm MP. 
 
2.4 Molecular biology techniques 
2.4.1 Nucleic acids precipitation 
The DNA was precipitated by adding 1/3 volume 7.5 M ammonium acetate (pH 5) and 
2.5 volumes ethanol (100%) to the aqueous solutions for 1-2 hours at -80°C or over night 
at -20°C. Afterwards the samples were centrifuged at 13000xg for 30 min at 4°C and the 
pellet was washed in 500 µl 70% Ethanol. After another centrifugation step at 1300 xg for 
10 min. the supernatant was removed completely. The pellets were air dried and 
dissolved in water or TE. 
 
2.4.2 Phenol Chloroform extraction 
For purification of the DNA the samples were extracted by phenol/chloroform following by 
precipitation (2.4.1). An equal volume of RotiTMPhenol was added to the DNA sample and 
mixed. The samples were centrifuged at 1300 xg for 5 min at RT. The upper aqueous 
solution was removed and combined with an equal volume of chloroform, following by 
centrifugation (1300xg, 5 min, RT). The DNA of the aqueous solution was precipitated as 
mentioned before (2.4.1). 
 
2.4.3 Determination of DNA concentrations 
The DNA concentrations were determined photometrically and calculated from the 
absorbance measured at 260 nm: c(DNA) = absorbance(260 nm) x 50 µg/ml and c(RNA) 
= absorbance(260nm)x40 µg/ml.  
If the DNA concentrations were to low, the concentrations were determined on ethidium 
bromide plates by comparing the signal intensity with serial dilutions of a DNA sample 
with known concentration. Therefore 100 ml of 0.8 % agarose in TAE buffer containing 1 
µg/ml ethidium bromide was added and the solution was plated in five petri dishes. The 
standards were prepared by seven serial dilutions in 100 mM EDTA in a range of 10 
ng/µl to 200 ng/µl and stored at -20°C. The same amount of 1 µl of the standards and the 
samples were spotted on the plates and incubated at RT for 15 min. The DNA was 
detected at 302 nm using the ‘Easy Enhanced Analysis System’ (Herolab). 
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2.4.4 DNA electrophoresis on agarose gels 
The DNA was diluted in DNA sample buffer and separated on horizontal agarose gels 
(0.6 to 1.5 % agarose in TBE buffer).  Agarose gels in TAE buffer containing ethidium 
bromide were used for extraction of DNA from the gels. Electrophoresis was performed 
at 5 V/cm in TBE buffer. The DNA was detected after staining in ethidium bromide 
(50 µg/ml) at 302 nm. For documentation the ‘Easy Enhanced Analysis System’ 
(Herolab) was used.  
 
2.4.5 General cloning approaches 
2.4.5.1 Digestion and dephosphorylation of DNA 
Digests of DNA were performed using the restriction enzymes and reaction buffers 
following the manufacturers instructions (New England Biolabs). 2 µg of DNA were 
incubated with 5 U of enzyme in a total volume of 50 µl. The digests were incubated over 
night at temperatures indicated by the manufacturers. For analytical digests, 1 µg of 
plasmid DNA was incubated for 2 hours with 5 U of enzyme.  
 
To avoid self ligation of vector fragments, the 5´-phosphate groups of vector DNA were 
removed by adding 1 U of calf intestine alkaline phosphatase (NEB) per µg of vector 
DNA and incubate at 37°C for 15 min. 
 
2.4.5.2 DNA extraction from agarose gels 
After restriciton enzyme digests the DNA was separated on an agarose gel and the 
desired fragments were excised from the gel. ‘Qiaquick PCR Purification Kit’ (Qiagen) 
was used for further purification following the manufacturers instructions. The excised gel 
fragments were solved in 300 µl buffer QG per 100 mg gel at 50°C and applied to a 
Qiaquick column. The column was centrifugated at 13000 xg for 1 min and the flow 
through was discarded.  After one washing step with 500 µl buffer PE, bound DNA was 
eluted in 50 µl EBC (10 mM Tris-Cl pH 8.5).   
 
2.4.5.3 DNA ligation  
For ligation of DNA fragments 30 ng of digested (and if necessary dephosphorylated) 
vector DNA and a 3 molar excess of the respective insert were incubated with 1 U of T4-
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DNA-Ligase (NEB) in 20 µl ligation buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCl2, 1 mM 
ATP, 10 mM DTT, 25 µg/ml BSA). After incubation over night at 16°C the ligation was 
transformed into competent E.coli cells.  
The sequencing of constructs generated by PCR amplification steps was done by the 
companies MWG or GATC. 
 
2.4.5.4 Analytical plasmid preparation 
The ‘Qiaprep spin Miniprep Kit’ was used for analytical plasmid preparation following the 
manufacturers instructions. A single bacterial colony was transferred from a selective 
agar plate into 3 ml of LB medium containing the appropriate antibiotic. The bacteria 
were incubated for 12-16 h at 37°C and 250 rpm. For the plasmid preparation 2 ml of the 
bacteria culture were harvested for 1 min at 13000xg at RT and resuspended in 250 µl 
buffer P1 (50 mM Tris/HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNaseA). Afterwards 250 µl 
of buffer P2 (1 % SDS, 0.2 M NaOH) and 350 µl of chilled buffer P3 (3.0 M potassium 
acetate, pH 5.5) were added, each buffer addition was followed by a cautions mixing 
step. After centrifugation (10 min, 13000xg, RT) the supernatant was applied on a 
Qiaprep spin column. The column was washed with 750 µl buffer PE and the DNA eluted 
with 50 µl TE buffer.   
 
2.4.5.5 Preparative plasmid preparation 
The ‘Qiagen plasmid Kit Midi’ was used for the preparative plasmid preparation following 
the manufacturers instructions. A single bacterial colony from a selective agar plate was 
inoculated in 100 ml LB containing the appropriate antibiotic. The culture was incubated 
for 12-16 h at 37°C and 200 rpm. The bacteria were harvested (15 min, 6000xg, 4°C)  
and resuspended in 4 ml buffer P1 (50 mM Tris/HCl pH 8.0, 10 mM EDTA, 100 µg/ml 
RnaseA). 4 ml buffer P2 (1 % SDS, 0.2 M NaOH) were added and after a cautious 
mixing bacteria were lysed for 5 min at room temperature. 4 ml of chilled buffer P3 (3.0 M 
potassium acetate, pH 5.5) were added, the sample was cautiously mixed again and 
incubated on ice for 15 min. The samples were centrifuged (30 min, 20000xg, 4°C) and 
the supernatant was poured over a filter and applied to a QIAGEN-Tip 100 column 
equilibrated in QBT buffer (750 mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 
0.15% (v/v) TritonX-100). The columns were washed two times with 10 ml QC buffer 
(1 M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) and the bound plasmid DNA was 
eluted in 5 ml QF buffer (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% isopropanol). 3.5 ml 
isopropanol were added to the eluent and the samples were centrifuged (30 min, 
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20000xg, 4°C). The DNA pellet was washed with 2 ml ethanol (70 %), centrifuged again 
(15 min, 20000xg, 4°C), air dried, resuspended in 100 µl TE buffer and stored at -20°C. 
The DNA concentration was determined as described in 2.4.3.  
 
2.4.5.6 Preparation of chemically competent E.coli 
Chemically competent cells were produced following the protocol of Molthoff et al., 
(1990). Briefly the E. coli were grown on selective LB agar plates containing the 
appropriate antibiotic. One colony was transferred to 2 ml SOB media and incubated at 
37°C over night. 1ml of the culture was inoculated into 200 ml SOB medium and 
incubated for 1-2 days (200 rpm) at 18°C until an OD600nm of 0.6 was reached. The 
culture was harvested (2000xg for 10 min at 4°C) and the pellet resuspended in 1/3 of 
the original volume cooled TB (250 mM KCl, 10 mM Hepes free acid, 15 mM CaCl2, 55 
mM MgCl2). Another centrifugation step was performed (2000 xg for 10 min. at 4°C) and 
the pellet was dissolved in 1/12 of the original volume TB. After addition of DMSO to a 
final concentration of 7%, 100 µl cells aliquots were immediately frozen in liquid nitrogen 
and stored at -80°C.  
 
2.4.5.7 Transformation  
For the transformation of chemically competent E. coli, 100 µl of the bacteria were 
thawed on ice for 10 min.  Afterwards 10 ng of plasmid DNA or 20 µl of ligation mix 
(2.4.5.3) were added and incubated on ice for 30 min. The cells were subjected to a heat 
shock at 42 °C for 50 s followed by incubation on ice for 2 min. After adding of 1 ml LB- 
medium the bacteria were incubated for 1 h at 37°C and plated on selective LB-agar 
plates containing the appropriate antibiotics. 
 
2.4.5.8 Preparation of electrocompetent YZ 2000 
The bacterial strain YZ 2000 was purchased from Gene Bridges and the 
electrocompetent cells were prepared using a combined protocol of Zhang et al. (1998) 
and the manufacturer’s instructions. YZ 2000 were grown on LB agar plates at 37°C and 
one colony was inoculated in 10 ml LB medium and incubated over night at 37°C and 
250 rpm. The culture was diluted 100-fold in LB medium and grown to an OD600nm of 0.5. 
The cells were chilled on ice for 30 min and centrifuged at 5000 rpm for 15 min at -5°C. 
The pellet was washed three times in 10% ice-cold glycerol. Bacteria were harvested at 
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6000 rpm for 15 min at -5°C and resuspended in 600µl 10% ice-cold glycerol. 40 µl 
aliquots were immediately frozen in liquid nitrogen and stored at -80°C. 
 
2.4.5.9 Homologous recombination in YZ 2000 
The bacterial strain YZ 2000 was electroporated according to the manufacturers 
instructions. 40 µl competent YZ 2000 were thawed on ice and both 0,4 µg vector and 
0,2 µg PCR-product were added and incubated on ice for 10 min. The mixtures were 
transferred into a 0.2 cm cuvette and placed into a Bio-Rad electroporator. The samples 
were pulsed once with 2.5 kV, 200 ohms and 25 µF. 1 ml of LB medium was immediately 
added and the cell suspension was transferred into a 1,5 ml eppendorf tube and 
incubated for 70 min at 37°C and 600 rpm. Samples were spread on selective LB-agar 
plates containing the appropriate antibiotics and incubated at 37°C for 12-16 h.  
 
2.4.5.10 Preparation of E.coli DMSO stocks 
For long time storage, 930 µl of an E.coli over night culture was mixed with 70 µl DMSO 
(final 7%) and frozen at -80°C.  
 
2.4.5.11 Polymerase chain reaction (PCR) 
2.4.5.11.1 DNA amplification for cloning 
For cloning procedures the DNA was amplified by PCR using 10 ng of plasmid DNA or 
genomic DNA, sense and antisense primer (25 pmol each), 2,5 U Pfu-polymerase 
(Stratagene), dNTP´s (20 µM each) and 5% DMSO were mixed in a total volume of 50 µl 
1xPCR buffer (Stratagene). The PCR-mix was initially denatured at 94°C for 5 min in a 
thermocycler followed by 30 consecutive cycles of: 45 s denaturing at 95°C, 45 s 
annealing of the oligonucleotide primers (5°C below their calculated melting point) and 
elongation at 72°C for 130 s with increasing the elongation time in each round for 5 sec. 
PCR reaction were either performed using the ‘GeneAmp System 2400’ (Perkin Elmer) 
or the ‘T1-Thermocycler’ (Biometra). The PCR products were cleaned up by using the 
‘Qiaquick PCR purification kit’. The samples were mixed with 5 volumes of buffer PB and 
applied on a Qiaquick column. After centrifugation for 1 min at 13000xg, the column was 
washed with 750 µl buffer PE and bound DNA fragments eluted in 50 µl TE.  Afterwards 
the DNA concentration was determined on ethidium bromide agarose plates (2.4.3) and 
directly used for restriction digests (2.4.5.1). 
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2.4.5.11.2 Analysis of L. major GLF gene deletion mutants by PCR 
To proof the correct insertion of the resistant marker cassettes into the Leishmania 
genome, the obtained clones were subjected to a 5’ and 3’ PCR reaction. In the 5’ PCR 
reaction, a sense primer (BK9) was designed that bound 5’ to the 5’ flanking region used 
for homologous recombination. The antisense primer (ACM99: Hyg, ACM101: Phleo) 
was directed against the 5’ end of the resistance marker to yield a PCR product of about 
1.5 kb. For the 3’ PCR reaction, the sense primer was directed against the 3’ end of the 
resistant marker (ACM 100: Hyg, ACM102: Phleo), while the antisense primer (BK12) 
annealed to a sequence 3’ of the 3’ flanking region used for homologous recombination, 
The 3’ end the PCR product comprehended 1700 nucleotides. For a 20 µl reaction, 10 ng 
genomic DNA, 4 pmol of sense and antisense primer, dNTP´s (20 µM each), 0.5 U Taq 
polymerase and 5% DMSO were mixed in 1x PCR buffer (Sigma). After 7 min of a initial 
denaturation at 94°C, the PCR-mix was incubated in a Thermocycler for 30 of the 
following cycles: 45 sec denaturation at 94°C, 45 sec annealing at 61°C, 1,30 min 
elongation at 72°C with increasing the elongation time in each round for 5 sec.. For the 
final step, a 10 min elongation at 72°C was applied. Afterwards the samples were loaded 
on a 1% agarose gel and visualized with ethidium bromide (2.4.4). Clones that were 
positives for both reactions were further analysed by Southern Blotting (2.4.15). 
 
2.4.5.11.3 Digoxigenin (DIG) labelled DNA probes 
A mix containing 2 mM dATP/dGTP/dCTP, 1.3 mM dTTP and 0.7 mM DIG-11-dUTP was 
used to prepared DIG-labelled DNA probes. For the amplification of the DNA probes, 10 
ng of plasmid DNA (pCR2.1hyg, pCR2.1phleo, p5’UTR-Topo, pET Leis-mut) 4 pmol of 
sense and antisense primer (Hyg probe: ACM85/ACM86; Phleo probe: ACM87/ACM88; 
UGM probe: HB1/HB2, 5’UTR probe: BK13/BK14), 5 µl of dNTP mix and 1.25 U Taq 
polymerase in a total volume of 50 µl in 1x Taq PCR buffer were mixed. After 7 min of an 
initial denaturation step at 94°C, the PCR-mix was incubated in a Thermocycler for 30 of 
the following cycles: 45 s denaturation at 94°C, 45 s annealing at 58°C (Hyg and Phleo 
porbe) or 64°C (UGM and 5’UTR), 1 min elongation at 72°C. In a final step, a 10 min 
elongation at 72°C was applied. With the exception of the 5’UTR probe that was gel 
purified (2.4.5.2) after synthesis, the PCR products were directly used in Southern Blot 
analysis. 
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2.4.6 Extraction of genomic DNA from L. major 
For the extraction of genomic DNA from L. major, 1x108 cells were centrifuged (1300xg, 
10 min 4°C) and resuspended in 400 µl TELT (50 mM Tris/HCl, pH 8.0, 62.5 mM EDTA, 
2.5 M LiCl, 4% Triton X-100).  After 5 min incubation at RT, 400 µl RotiTMPhenol was 
added and mixed for 5 min at 4°C.  Samples were centrifuged for 10 min at 14000xg and 
4°C to separate the two phases. The upper phase was mixed with 400 µl 
chloroform/isoamylalcohol (24:1), incubated for 5 min at 4°C and centrifuged as before. 
DNA present in the aqueous phase was mixed with 1 ml ethanol (100%), incubated on 
ice for 5 min and centrifuged. The DNA pellet was washed with 1 ml ethanol (70%), 
centrifuged, dried, resuspended in 100 µl TE and stored at 4°C. 
 
2.4.7 Southern Blotting 
2.4.7.1 Preparation of the Southern Blots 
2,5 µg DNA was digested with 5 U enzyme in a total volume of 25 µl at 37°C over night.  
The digested samples and 1ng of PCR product of the corresponding DNA probe were 
separated on a 0.7% agarose gel containing 5 µg/ml ethidium bromide. The gel was then 
incubated with 250 mM HCl for 15 min to depurinate the DNA and two times for 10 min in 
denaturing solution (0.5 M NaOH, 1.5 M NaCl). The DNA fragments were transferred to a 
nylon membrane by capillary forces in denaturing solution over night. The set up is 
described in the following: 
1 glass plate 
1 thick whatmann filter paper soaked in denaturing solution 
1 thin whatmann filter paper soaked in denaturing solution 
agarose gel up side down 
nylon membrane, soaked in denaturing solution 
3 thin whatmann filter paper, soaked in denaturing solution 
6 layer dry cellulose filters 
glass plate  
0,5 kg weight 
 
The following day the blot membrane was washed for 10 min in 50 mM sodium 
phosphate buffer pH 7.2 at RT and dried. UV crosslinking (Stratalinker, Stratagene) was 
used to fix the DNA to the membrane. The membrane was hybridised and developed as 
described in 2.4.7.2 and 2.4.7.3. 
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2.4.7.2 Hybridisation of Southern Blots 
The membrane was prehybridised in high SDS (7% SDS, 50% formamid, 5x SSC, 50 
mM NaPO4, pH 7.0, 0.1% N-lauroyl sarcosine, 2% blocking solution (Roche) for 1 hour  
at 42°C. The DIG-labelled probe was mixed with an equal volume of TE, denaturated at 
95°C and transferred on ice to cool down.  The solution was incubated with the 
membrane in high SDS (7% SDS, 50% formamid, 5x SSC, 50 mM NaPO4, pH 7.0, 0.1% 
N-lauroylsarcosine, 2% blocking solution (Roche)) for 1 hour  at 42°C. The membrane 
was incubated shortly with 1 x SSC (0.1% SDS), following by two washing steps with 
2xSSC (0.1% SDS) for 15 min at RT. The membrane was washed another two times with 
0.1x SSC (0.1% SDS) for 30 min at 65°C. The bound probe was detected with CSPD 
(2.4.7.3). 
 
2.4.7.3 Detection of Southern Blots by chemiluminescence 
The membrane was equilibrate in buffer 1 (0.1 M maleic acid, 0.15M NaCl, pH 7.5) and 
blocked with buffer 2 (10x blocking solution (Roche) diluted 1:10 in buffer 1) for 30 min. 
Afterwards the membrane was incubated with AP-coupled α-DIG Fab fragment (1:10000 
in buffer 2) for 30 min at RT. The membrane was washed three times with buffer 1 
containing 0.3% Tween, equilibrate in buffer 3 (100 mM Tris/HCl pH 9.5, 100 mM NaCl) 
and incubated with 10-12 drops of CSPD (Disodium 3-(4-methoxyspiro {1.2-dioxetan-
3.2’-85’-chloro} –tricyclo decan} -4-yl)phenylphosphate, Roche) for 15 min at 37°C. The 
CSPD was removed and the membrane sealed into plastic foil. Due to dephosphorylation 
of the CSPD by the AP activity, light was emitted at 477 nm. The signals were visualized 
on Hyperfilms MP. 
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3 Results 
3.1  Identification and Characterisation of the UDP-      
galactopyranose mutase from Leishmania major 
3.1.1 Analysis of the amino acid sequence 
The UDP-galactopyranose mutase (UGM), encoded by the GLF gene, is a flavoprotein 
that catalyzes the rearrangement of UDP-galactopyranose into UDP-galactofuranose 
(Figure 7). As the latter is the donor for all galactofuranosyltransferases, UGM represents 
a central enzyme in Galf metabolism. Although the first prokaryotic GLF was identified in 
1996, previous effort to detect eukaryotic GLFs had not been successful. So not 
surprisingly, no sequence highly homologous to bacterial UGMs could be found in 
Leishmania major genome. However as the flavin cofactor is indispensable for catalytic 
activity of bacterial UGM (Nassau et al., 1996, Köplin et al., 1997, Soltero-Higgin et al., 
2004a), we hypothesized that eukaryotic UGMs are also flavoproteins. Several 
sequences with conserved sequence motifs for FAD binding were identified in blast 
searches. Sequences exhibiting the dinucleotide binding motif 
xhxhGxGxxGxxxhxxh(x)8hxhE(D) where h is a hydrophobic residue (Wierenga et al., 
1983) were closely examined. This motif located at the N- terminus is characteristic of 
proteins of the glutathione reductase structural family (GR) including E.coli UGM 
(Sanders et al., 2001b). Amongst protein sequences containing this motif, a candidate 
gene showing an overall identity of 18% with E.coli UGM was selected. The putative 
enzyme contained most of the amino acid residues involved in substrate binding, 
residues that are highly conserved within the bacterial UGMs (Figure 8). Additionally, a 
gene showing 51% identity to the Leishmania candidate was present in the genome of 
Aspergillus fumigatus, an organism known to synthesise Galf, while no homologous 
genes were found in other completely sequenced eukaryotic genomes like Drosophila 
melanogaster, Arabidopsis thaliana, yeast or mammal, organisms in which Galf has 
never been found.  
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....MSADKVVIIGAGPTGLGAAVRLMELKHANFHLYDGGTVPGGLSRS. 
MTHPDISVDVLVIGAGPTGLGAAKRLNQIDGPSWMIVDSNETPGGLAST. 
....MKSKKILIVGAGFSGAVIGRQLAEKGHQV.HIIDQRDHIGGNSYDA 
......MYDYIIVGSGLFGAVCANELKKLNKKV.LVIEKRNHIGGNAYT. 
                     1         
____________________________      __
 
 
.VLDDKGFLWDMGGHVIFSHYAYF.DDVMNLAI...SDWNTLQRESWVRC 
.DVTPEGFLYDVGGHVIFSHYKYF.DDCLDEALPKEDDWYTHQRISYVRC 
RDSETNVMVHVYGPH.IF.HTDNETVWNYVNKHA.EMMPYVNRVKATVNG 
.EDCEGIQIHKYGAH.IF.HTNDKYIWDYVNDLV.EFNRFTNSPLAIYKD 
                    43                   * 
 
SGAWVPYPFQSNIHRLPPEVRDTCLKGIEEAEAARSVAAPEKPQNFAEYV 
QGQWVPYPFQNNISMLPKEEQVKCIDGMIDAALEARVAN.TKPKTFDEWI 
QVFSLPINLHTINQFFSKTCSPDEARALIAEKGDSTIAD...PQTFEEQA 
KLFNLPFNMNTFHQMWGVK.DPQEAQNIINAQKKKYGDKV..PENLEEQA 
                    89 
 
SRHFGEGIAEVFMRPYNFKVWAVPLHLMSTEWVGERVAAVNVERIRENIQ 
VRMMGTGIADLFMRPYNFKVWAVPTTKMQCAWLGERVAAPNLKAVTTNVI 
LRFIGKELYEAFFKGYTIKQWGMQPSELPAS..................I 
ISLVGEDLYQALIKGYTEKQWGRSAKELPAF..................I 
                   136               *   ** 
 
LKRDDVGWGPNATFRFPKSGGTGAIYKAVWKMIPEAHKTLGPQCRVTKVN 
LGKTAGNWGPNATFRFPARGGTGGIWIAVANTLPKEKTRFGEKGKVTKVN 
LKRLPV........RFNYDDN...YFNHKFQGMPKC ............. 
IKRIPV........RFTFDNN...YFSDRYQGIPVG ............. 
                   168  *                     ** 
 
PITKTLTMANGEAVSYDALVSTMPLDDLLLAVAAGVEEDAETASASALKA 
ANNKTVTLQDGTTIGYKKLVSTMAVDFL................AEAMND 
..............GYTQMIKSI....LNHENIKVDLQREFI.VEERTHY 
..............GYTKLIEKM....LEGVDVKLGIDFLKDKDSLASKA 
                   193 
 
PRLREIADKMVYSSTHIIGIGVKGCPPPEMRTACWLYFPEDGIPF..YRA 
QELVGLTKQLFYSSTHVIGVGVRGSRPERIGDKCWLYFPEDNCPF..YRA 
DHVFYSGPLDAFYGYQYGRLGYRT...........LDFKKFTYQ.GDYQG 
HRIIYTGPIDQYFDYRFGALEYRS...........LKFETERHEFPNFQG 
                   225                      *            * 
 
TIFSRYADTNAPEGH........................WSILLEVSQNV 
TIFSNYSPYNQPEASKKLPTMQLADGSRPQSTEAKEGPYWSIMLEVSESS 
CAVMNYCSVDVPYTR................................... 
NAVINFTDANVPYTR................................... 
                   264              * 
 
LYKPVNVDTIVEDCIAGLRTVTLLRPEDEIVSRWHHMEKKGYPIPFVGRN 
M.KPVNQETILADCIQGLVNTEMLKPTDEIVSTYHRRFDHGYPTPTLERE 
........ITEHKYFSPWEQHDGSVCYKEYSRACEENDIPYYPIRQMGEM 
........IIEHKHFDY.VETKHTVVTKEYPLEWKVGDEPYYPVNDNKNM 
                   279                            *            * 
 
ELLEEVQPVLRDKYQIYSRGRFGAWRYEVANQDHSLMQGVEAVGHIFYGT 
GALTQILPKLQDK.DIWSRGRFGSWRYEVGNQDHSFMLGVEAVDNIVNGA 
ALLEKYLSLAENETNITFVGRLGTYRY....LDMDVTIA.EALKTAEVYL 
ELFKKYRELASREDKVIFGGRLAEYKY....YDMHQVIS.AALYQVKNIM 
                   320                          *     * 
 
                  DEDTVHKPEKVNTRRGEMRCTWSSTAS....... L. major 
                  VELTLNYPDFVNGRQNTERRLVDGAQVFAKSKAQ A. fumigatus 
                  NSLTENQPMPVFTVSVR................. K. pneumoniae 
                  STD............................... E. coli 
                   365 
 
 
Figure 8: Alignment of key eukaryotic and prokaryotic GLF proteins.  Conserved residues of L. major, 
A. fumigatus, K. pneumoniae and E. coli K12 UDP-galactopyranose mutase are boxed. The asterisks 
indicate the E. coli substrate binding site. The dinucleotide binding motif is underlined. Numbers refer to the  
E. coli sequence. 
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3.1.2 In vivo activity assay 
The activity of the L. major UGM was tested in an in vivo complementation system, 
adapted from the assay described by Köplin et al. (1997) for the characterisation of 
Klebsiella pneumoniae UGM. In gram-negative bacteria the O-antigen of the 
lipopolysaccharide (LPS) is encoded by a gene cluster called rfb. The rfb gene cluster of 
K. pneumoniae O1 containing an in frame deletion in glfKPO1 gene, was introduced into 
the plasmid pWQ70 (Köplin et al., 1997). After introduction into E. coli CWG287, a strain 
deleted for the endogenous rfb cluster, no LPS biosynthesis could occur. However when 
an additional plasmid containing the glfKPO1gene was transformed, LPS biosynthesis was 
restored (Köplin et al., 1997). To analyse the activity of the putative L. major UGM, the 
candidate gene was amplified by PCR from genomic DNA digested with NdeI and XhoI 
and cloned into the vector pET22b. The resulting plasmid was then transformed with the 
plasmid pWQ70 into E. coli CWG287. The LPS phenotype conferred by these plasmids 
was first analysed by susceptibility to the phage Ffm (Wilkinson et al., 1972). The 
candidate gene of L. major like the characterised K. pneumoniae glfKPO1 conferred 
resistance to the phage (Figure 9), suggesting that the LPS biosynthesis was restored. In 
contrast bacteria containing pWQ70 and an empty vector were susceptible to the phage 
Ffm, resulting in phage plaque formation. The LPS biosynthesis was further analysed by 
SDS-PAGE and silver staining. If the CWG287 bacteria contained pWQ70 and the 
characterised K. pneumoniae glfKPO1 gene or the candidate gene from L. major, a ladder 
of smooth LPS could be detected, indicating that the gene transformed are functional. As 
expected no LPS biosynthesis was observed with an empty vector control (Figure 10).                             
 
 
 
 
 
 
 
 
 
Figure 9: Resistance of E. coli CWG287 (pWQ70) to phage Ffm after transformation with a functional 
GLF gene.  E. coli CWG 287 was transformed with pWQ70 (A) and the gene encoding K. pneumoniae (B)  
or Leishmania major (C) UDP-galactopyranose mutase. 
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Figure 10: Silver staining of the LPS of E. coli CWG 287 after transformation with GLF from K. 
pneumoniae or L. major.   
 
3.1.3 In vitro testing of L. major UGM 
The activity of L. major UGM was analysed using an in vitro assay. The assay (Figure 
11) is based on the release of tritiated formaldehyde by periodate oxidation from the 
product UDP-[6-3H]Galf but not from its precursor UDP-[6-3H]Galp (Scherman et al., 
2003). Radioactive product and precursor can then be easily separated by anion 
exchange chromatography. E. coli CWG288, a derivate from CWG287 was used to 
express the different UGMs. This strain is deficient in endogenous UGM and in UDP-
glucose-4-epimerase, an enzyme that converts UDP-Galp in UDP-Glucose. 
Consequently crude protein extract can be used for this assay. The reaction catalysed by 
the mutase is a reversible reaction in which the production of UDP-Galf is disfavoured. 
Only 5 to 7% of UDP-Galf would be present at the equilibrium. The activity of the different 
enzyme tested was comparable. The average values from three independent 
experiments using L. major and K. pneumoniae enzymes were 4.3% and 3.6%, 
respectively, of total UDP-Galp used in the experiment. A background of 2.1% was 
observed with bacteria containing only an empty vector. These data suggested that the 
L. major GLF gene encodes a protein with UGM activity that promotes the formation of 
UDP-Galf from UDP-Galp.  
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Figure 11: Assay for UDP-galactopyranose mutase.  UDP-Galf but not UDP-Galp forms neutral tritiated 
formaldehyde when treated with sodium periodate (from Scherman et al., 2003).  
 
3.2 Generation of a L. major GLF gene deletion mutant  
In parasites of the Trypanosomatidae family, gene regulation and expression are 
characterised by a combination of atypical mechanisms. The genes in Leishmania do not 
contain any intron like in other eukaryotes and are separated by short intergenic regions. 
Promoters are absent and the transcription takes place in a polycistronic fashion (Borst 
et al., 1986, Kapler et al., 1990). The long polycistronic pre-mRNAs are then processed 
by coupled trans-splicing and polyadenylation reactions to generate mature 
monocistronic mRNAs, each of which bears at its 5´end a common 39-nucleotide mini-
exon. Sequences within the intergenic regions provide the signals for these processes as 
well as regulation of gene expression (Curotto de Lafaille et al., 1992, Stiles et al., 1999, 
Liang et al., 2003).  Furthermore, Leishmania are diploid asexual parasites thus deletion 
of any gene requires two rounds of targeted replacement to substitute each allele by a 
dominant drug-resistance marker. Our strategy for the obtaining of a targeted gene 
deletion mutant was influenced by the peculiarities in the mechanisms of gene 
expression used by trypanosomatids. Notably, the targeting constructs were prepared by 
Red/ET recombination in bacteria in order to leave the 5´and 3´ untranslated regions 
(UTRs) completely unaltered and allow correct expression of the dominant markers in 
Leishmania.  
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3.2.1 GLF is a single copy gene in L. major 5ASKH 
Another particularity of Leishmania and other kinetoplastida organisms is that many 
genes are present in the genome as multiple copies. In L. major, most of these multiple 
copies genes occur in 2 or more separate loci containing single genes and/or tandem 
arrays (Ivens et al., 2005). When we initiated this project, Leishmania genome was 
incomplete and copy number of the GLF gene in L. major 5ASKH genomic DNA was 
thus investigated by Southern Blot. Sequence information could however be retrieved 
from the L.major genome sequencing project (The Wellcome Trust Sanger Institute) to 
reconstitute GLF locus. Genomic DNA was digested with Acc I, Nsi I, Pst I or Sma I in 
order to generate different diagnostic fragments as indicated in Figure 12a. Digests were 
then separated on a 0.7 % agarose gel, transferred to nitrocellulose and hybridised with 
a digoxigenin (DIG) labelled GLF probe consisting of the whole open reading frame.  As 
expected fragments of approximately 4.1 kb, 4.7 kb and 3.4 kb were observed after 
digestion with Nsi I, Pst I and Sma I, respectively. Digest with Acc I gave rise to two 
signals of 0.9 kb and 0.6 kb as it cuts once in the GLF sequence. No additional bands 
could be observed indicating the presence of a single copy gene (Figure 12b). This result 
is consistent with the presence of a single homologous of GLF present on chromosome 
18 as revealed after completion of Leishmania major genome (Ivens et al., 2005).  
Moreover the presence of a single copy gene was later confirmed by targeted gene 
replacement of GLF. 
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Figure 12: Investigation of the number of GLF gene copies 
a) Schematic representation of L. major GLF locus indicating Acc I, Nsi I, Pst I or Sma I fragments expected 
after hybridisation with a GLF probe. 
b) Southern blot analysis of genomic L. major 5 ASKH DNA.  Genomic DNA was digested with Acc I, Nsi I, 
Pst I or Sma I. After separation on a 0.7% agarose gel, the fragments were transferred to a nitrocellulose 
membrane and hybridised with a DIG-labelled glf probe. 
 
3.2.2 Cloning of the targeting constructs 
As we have already emphasized it, two successive rounds of targeted gene replacement 
are required to inactivate any leishmanial gene because of the diploidy of this parasite. 
Two different targeting constructs in which the regions flanking the GLF gene are 
separated by an antibiotic resistance gene were thus necessary. For the generation of 
these constructs, a 1.5kb region directly upstream of the start codon and a 1.5kb region 
directly downstream of the stop codon were amplified by PCR from L .major genomic 
DNA and successively cloned into the vector pBSK+ (Stratagene) resulting in  a plasmid 
called 5’3’pBSK+. Sequence information was available from L.major genome sequencing 
project (Welcome Trust Sanger Institute). The genes encoding hygromycin 
phosphotransferase (hyg) and phleomycin binding protein (phleo) that give resistance 
against the antibiotics hygromycin and phleomycin respectively were chosen amongst 
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the suitable selection markers and inserted between the 5’- and 3’-UTR of GLF gene by 
Red/ET recombination in bacteria. For this purpose, the open reading frames of the 
antibiotic resistance genes were amplified by PCR from plasmid pCR2.1hyg and 
pCR2.1phleo using primers having a homologous overhang of approximately 35bp to the 
end of the 5’-UTR or to the start of the 3’-UTR of GLF. These PCR products were then 
separately electroporated in E. coli YZ2000 (Gene Bridges, Germany) with the digested 
plasmid 5’3’pBSK+ to promote the insertion of the selection marker between the 5’- and 
3’-UTR of GLF by homologous recombination. This procedure yielded two targeting 
plasmids called 5’3’Hyg pBSK+ and 5’3’Phleo pBSK+ in which the antibiotic resistance 
gene replaces precisely GLF gene. This particular point is important for correct 
expression of the selection markers once inserted in Leishmania genome.  
 
3.2.3 Targeted gene deletion of L.major GLF 
Most trypanosomatid species grow rapidly in standard culture media with doubling time 
of 6 to 10 hours. Moreover colonies can be obtained by plating on semi-solid media, so 
several rounds of genetic manipulation can be carried out in a reasonable amount of 
time. The targeting constructs, carrying the hygromycin and phleomycin resistance genes 
were first excised from plasmids 5’3’Hyg pBSK+ and 5’3’Phleo pBSK+ by digestion with 
Xho I and Sac I yielding fragments of 4.2 kb and 3.6 kb respectively. The later were 
purified by agarose gel electrophoresis, gel extraction and ethanol precipitation. In the 
first round, 2 µg of each fragment were separately electroporated in 1x 108 L. major wild 
type 5ASKH. To isolate clonal lines, the parasites were grown on agar plates containing 
the appropriate selective drug. Visible colonies of parasites were observed after 10 days 
at 27°C. More hygromycin (GLF/∆glf::HYG) than phleomycin (GLF/∆glf::PHLEO) 
resistant clones were obtained in the first electroporation round. This reproducible result 
suggests that the integration of the phleomycin resistance gene was more difficult than 
the hygromycin resistance gene. In this regard, it is worth mentioning that the phleo gene 
is a 373 bp gene while hyg contains 1026 bp and has thus a size comparable to 
Leishmania GLF. After selection on agar plates, different clones were transferred to liquid 
media in order to prepare genomic DNA and DMSO stocks. The clones were first 
screened for correct insertion of the antibiotic resistant markers by PCR and positives 
clones were further analysed by Southern Blotting. Two representative phleomycin 
resistant clones that were subsequently used for the obtaining of homozygous mutants 
are shown in the Figures 13 and 14. Genomic DNA from wild type Leishmania and from 
different mutant clones was digested with Sac I or Pst I and analysed by Southern 
Blotting using a DIG labelled probe consisting of the whole coding sequence of 
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phleomycin to exclude random integration. The signals of 6.5 kb and 3.6 kb confirmed 
single integration into the genome at the GLF locus (Figure 13). No unspecific 
hybridisation in wild type parasites could be detected. 
 
 
Figure 13: Determination of random integration of the selection marker in phleomycin resistant 
clones. Genomic DNA from L. major phleomycin resistant clones and parental strain was digested with Sac I 
or Pst I and analysed by Southern Blotting (b). The blots were hybridised with DIG labelled phleomycin. The 
sizes of the expected fragments are shown in a). 
 
To confirm the integration of phleomycin at the right locus, the heterozygous mutants 
were further analysed by Southern Blotting using a 5’-UTR probe. A sequence lying 
outside the region previously used for homologous recombination was cloned into the 
vector pcR4-TOPO and the resulting plasmid used to generate the DIG-labelled 5’-UTR 
probe. Genomic DNA obtained from various heterozygous mutants and the parental 
strain was digested with Apa I or Sac I, separated on agarose gel, transferred to a 
nitrocellulose membrane and hybridised with this 5’-UTR probe. In all samples, presence 
of a wild type GLF allele was demonstrated by the fragments at either 5.4 kb or 4.3 kb 
when DNA is digested with Apa I or Sac I respectively (Figure 14). Additionally, the 
heterozygous mutants exhibit signals at 6.5 kb or 6.4 kb according to the restriction 
enzyme used, that confirm successful replacement of one GLF allele by the phleomycin 
resistant marker. The analyses described above allowed the isolation of L. major 
heterozygous mutants GLF/∆glf::HYG or GLF/∆glf::PHLEO and the confirmation of their 
identity. 
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Figure 14: Southern Blot analysis of the heterozygous mutants. Genomic DNA was digested either with 
Sac I or Apa I, transferred to nitrocellulose and hybridised with a 5’-UTR probe (b). The sizes of the expected 
fragments are shown in a). 
 
As mentioned before integration of the hygromycin resistance gene in L. major 5 ASKH 
genome seemed to be preferred over integration of the phleomycin resistance gene. 
Thus to ease the obtaining of homozygous mutants, GLF/∆glf::PHLEO clones were 
selected and electroporated with the purified Xho I – Sac I fragment obtained from the 
hygromycin targeting construct 5’3’Hyg pBSK+. Transfectants were selected on media 
containing both phleomycin and hygromycin and expanded in liquid culture for the 
preparation of genomic DNA and DMSO stocks. Like for the heterozygous mutants, the 
integration of the selection marker at the right locus was first investigated by PCR and 
later confirmed by Southern Blotting using different restriction enzymes and probes. At 
least two clones resistant to phleomycin and hygromycin obtained from each 
heterozygous GLF/∆glf::PHLEO clone were inspected. Genomic DNA of all clones as 
well as the parental strain were first digested with Nsp I, transferred to a nitrocellulose 
membrane and hybridised with a probe covering the whole coding sequence of 
hygromycin. As expected, a 1.9 kb fragment (Figure 15) was detected in the 
homozygous mutants only indicating the replacement of the second GLF allele. Since no 
other signal could be detected with this probe, random integration of the hygromycin 
resistant marker in the genome was excluded.  
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Figure 15: Determination of random integration of the hygromycin marker in homozygous mutants. 
Genomic DNA of wild type, heterozygous and homozygous mutants was digested with Nsp I and analysed 
by Southern Blotting (b). The blots were hybridised with DIG labelled hygromycin. The size of the expected 
fragment is shown in a). 
 
As previously, the result was confirmed with a DIG-labelled 5’-UTR probe (Figure 16). In 
the later case, genomic DNA was digested with Apa I. The signals at 6.5 kb and 7.2 kb 
observed in the homozygous parasites correspond to the predicted fragment obtained 
after integration of phleomycin and hygromycin respectively at the GLF locus. On the 
other hand, no signal at 5.4 kb indicative of a GLF allele is observed in these parasites 
while it is present in the heterozygous mutant and wild type strain. These data are 
consistent with the desired recombination events.  
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Figure 16: Southern Blot analysis of the homozygous mutants. Genomic DNA from wild type, 
heterozygous mutants and resulting homozygous mutants was digested with Apa I, transferred to a 
nitrocellulose membrane and hybridised with a 5’UTR probe (b). The scheme of the resulting fragments is 
depicted in a). 
 
The absence of the two GLF alleles in the homozygous mutant is clearly illustrated in 
Figure 17 presenting a Southern blot hybridised with the whole coding sequence of GLF. 
As expected, two fragments of 0.91 kb and 0.56 kb are observed after digestion of 
genomic DNA from wild type and heterozygous mutants with Acc I, whereas no signal is 
visible in the homozygous mutants. All these analyses demonstrate unambiguously the 
replacement of both GLF alleles in Leishmania major 5 ASKH. We were thus able to 
generate ∆glf::HYG/∆glf::PHLEO parasites further referred to as ∆glf mutant indicating 
that in contrast to mycobacteria, GLF is not essential for Leishmania major survival.  
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Figure 17: Confirmation of GLF deletion. Wild type, heterozygous and corresponding homozygous 
mutants were analysed by Southern blotting after Acc I digest using the complete coding sequence of the 
GLF as a probe. 
 
3.2.4 Re-expression of UDP-galactopyranose mutase in L. major ∆glf 
mutant 
As a control for subsequent experiments, the expression of the UDP-galactopyranose 
mutase (UGM) was restored in the deficient mutants in order to assign an observed 
phenotype to GLF. The complete coding region of GLF was PCR amplified and cloned 
into the Leishmania pXG(NEO) expression vector using Sma I and BamH I restriction 
sites respectively, yielding pXG-GLF. The cloning site of this episomal vector is flanked 
by the intergenic regions of Leishmania dihydrofolate reductase thymidylate synthase 
gene that provide signals for trans-splicing and polyadenylation and drive the expression 
of gene inserted between them. PXG gives high level of expression, fairly constant 
trough the parasite life cycle (Chakkalath et al., 2000). Additionally, it carries a neomycin 
resistance marker (neo) for selection of transfectants. To restore the expression of UGM, 
2x 108 L. major homozygous parasites were thus transfected with 10 µg of pXG-GLF. 
The resulting ∆glf::HYG/∆glf::PHLEO [pX-GLF] parasites further referred to as ∆glf/+GLF 
or “addback” were isolated on M199 agar plates containing phleomycin, hygromycin and 
neomycin. After 10 days of incubation at 27°C the colonies were visible and transferred 
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to liquid M199 media for preparation of cell pellets and DMSO stocks. In all further 
analyses, sibling clonal lines behaved similarly and thus results from a single ∆glf  and 
∆glf /+GLF mutant will be shown in illustrations. 
 
3.3 Characterisation of L. major ∆glf mutant 
In order to understand the effect of GLF deletion and thus of the galactofuranose 
metabolism on important biological processes related with the pathogenesis of 
Leishmania and link these effects to specific molecules, the generated mutants need to 
be biochemically defined. As galactofuranose is present in the cell surface 
glycoconjugates of Leishmania, particular attention was paid to these molecules.  
 
3.3.1 In vitro growth of ∆glf mutant  
The in vitro growth behaviour of several ∆glf mutant and the corresponding 
GLF/∆glf::PHLEO heterozygous mutant was first analysed. As shown in Figure 18 the 
heterozygous and homozygous mutants grew in culture as well as the parental wild type 
strain indicating that GLF is not critical for in vitro growth of Leishmania parasites. All 
parasites appeared morphologically normal under a light microscope. The growth of the 
∆glf/+GLF mutant was also comparable to wild type Leishmania. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: In vitro growth of ∆glf mutants. The cell count of wild type, heterozygous and the 
corresponding homozygous mutant were determined over 4 days using a light microscope. Results obtained 
from a representative heterozygous and homozygous mutant are presented. 
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3.3.2 Characterisation of L. major ∆glf cell surface glycoconjugates  
The cell surface glycoconjugate structures of Leishmania major have previously been 
characterised in detail. Galf is present in the anchor of the abundant polysaccharide LPG 
and in GIPLs, the major glycolipids of the plasma membrane. Thus deletion of GLF is 
expected to affect the biosynthesis of these molecules. Furthermore Leishmania present 
structurally related molecules such as the GPI-anchor of proteins or PPGs, which share 
some steps of the LPG and GIPLs biosynthetic pathways. Therefore the effect of a GLF 
targeted gene deletion on the expression of all these related cell surface glycoconjugates 
was investigated.  
 
3.3.2.1 Analysis of Lipophosphoglycan expression 
LPG is the major glycoconjugate structure on the cell surface of L.major promastigote 
parasites. It is distributed over the complete cell surface including the flagellum. 
Moreover LPG plays an important role in the pathogenesis of Leishmania. This 
polysaccharide constituted of -6Galβ1-4Manα1-P- repeat units is attached to the plasma 
membrane via a GPI anchor (McConville and Ferguson, 1993). Non infectious L. major 
procyclic promastigotes contain in average 14 repeat units while the infectious metacyclic 
promastigotes enriched in stationary phase culture bear 30 repeat units in average. 
Since the GPI-anchor connecting LPG to the membrane contains a β-D-Galf residue, 
LPG expression should be affected in ∆glf mutant due to absence of UGM. 
 
3.3.2.2 Western Blot analysis of LPG synthesis 
Synthesis of LPG in wild type, ∆glf and ‘add back’ (∆glf /+GLF) parasites was 
investigated by Western blotting. An equal amount of each cell lysate was separated on 
a ProSieve SDS PAGE and the Western blot was analysed with the monoclonal antibody 
(mAb) WIC79.3 recognising galactose substituted repeat units specific for L. major LPG 
and PPGs (Greenblatt et al., 1983). Signals were detected with an enhanced 
chemiluminescence (ECL) system. Equal loading of the cell lysates was confirmed by 
Commassie-Blue staining of a second gel. Due to microheterogeneity of the chain length 
(variation of number of repeat units), LPG appears as a diffuse distending signal between 
30 and 100 kDa (Figure 19). LPG expression was observed in the parental wild type 
strain while no signal was discernible in the homozygous mutants confirming absence of 
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LPG backbone. When UGM expression was restored, LPG biosynthesis was resumed as 
shown by the strong signal present in the ∆glf/+GLF. Hence as expected, absence of 
UGM leads to the complete absence of LPG backbone in the null mutant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Analysis of LPG by Western Blotting using the monoclonal antibody WIC79.3. a) Lysates of 
wild type, homozygous and corresponding add back mutant were separated on 10 % SDS ProSieve gel and 
analysed with WIC79.3 and ECL detection. b) To confirm, equal loading in each lane, a second gel was 
stained with Commassie-Blue. 
 
3.3.2.3 Analysis of phosphoglycans by immunofluorescence 
LPG expression of wild type, and ∆glf/+GLF was also analysed by immunofluorescence 
microscopy. Leishmania promastigotes were stained with the mAb WIC79.3 and a Cy3-
coupled secondary antibody and visualised by both immunofluorescence microscopy and 
transmitted light using the 40 x magnification. Wild type Leishmania show an intense 
staining revealing the abundance of LPG on the entire cell surface. In contrast no 
staining was detectable in the ∆glf mutant indicating the total absence of LPG (Figure 
20). LPG expression could be restored in the ‘add back’ mutant (∆glf/+GLF) confirming 
that the observed phenotype is specific for GLF deletion. Since UGM is overexpressed in 
the ‘add back’ mutant, a slight increase in fluorescence intensity is visible compared to 
wild type parasites.  
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Figure 20: LPG cell surface expression of L. major wild type, ∆glf and ∆glf/+GLF mutants.  
Immunofluorescence with mAb WIC79.3. Leishmania promastigotes were fixed and LPG stained with 
WIC79.3 (1:1000). Cells were visualised by transmitted light. 
 
3.3.2.4 Characterisation of PPGs in ∆glf mutants 
The family of proteophosphoglycans is constituted of secreted and membrane bound 
proteins that are expressed in a stage and species specific manner. For example, L. 
mexicana promastigotes secrete two different acid phosphatases and a filamentous 
PPG. In contrast, L. major synthesise fewer PPGs and does not secrete any acid 
phosphatase (SAP, secreted acid phosphatase).   
PPGs, like LPG, contain galactose substituted repeat units that can be recognised by the 
mAb WIC79.3. Thus membrane bound PPGs should be visible in the ∆glf- mutant by 
immunofluorescence using WIC79.3 antibody (Figure 20) while PPG expression should 
not be decreased by glf deletion. However, as mentioned above, no signal representing 
the corresponding epitope was visible on the ∆glf- mutant. This indicates the absence of 
membrane bound PPGs in L. major MHOM/SU/73/5ASKH. Since PPGs are high 
molecular weight structures they remain in the stacking gel and thus can be separated 
from LPG molecules. By western blotting of the stacking gel using WIC79.3 , membrane 
bound PPGs were analysed. However, no signals could be detected in wild type or 
mutant parasites confirming the lack of membrane bound PPGs. More surprisingly, the 
PPGs secreted in the media were hardly discernable after Triton X-114 partial purification 
and western blotting with WIC79.3 suggesting the low abundance of these molecules. 
Therefore the influence of GLF deletion on phosphogylcosylation of the PPGs was 
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analysed by heterologous expression of L. mexicana secreted acid phosphate (SAP) in 
L. major wild type and ∆glf-. SAP was immunoprecipitated from cell culture supernatant 
with the specific monoclonal antibody LT8.2 and the samples were analysed by Western 
blotting using the mAb WIC 79.3 (Figure 21, a).  Equal protein loading was confirmed by 
staining with the mAb LT8.2 (Figure 21, b). As expected, no signal was observed for 
untransfected wild type parasites (Figure 21, lane 1) confirming absence of SAP in L. 
major. On the other hand the slower electrophoretic mobility of SAP in ∆glf- relative to 
wild type suggests that the degree of phosphoglycosylation is elevated in ∆glf-.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Proteophosphoglycan analysis. WT, WT+SAP and ∆glf+SAP were grown for two days in 
serum free M199 media. The SAP protein was immunoprecipitated with mAb LT8.2 and analysed by 
Western blotting using mAb WIC 79.3 (a). Equal loading was confirmed by staining with the mAb LT8.2 (b).   
 
3.3.2.6 Characterisation of GIPLs in ∆glf null mutant 
Leishmania major GIPLs are important constituents of the plasma membrane containing 
one residue of galactofuranose. Sometimes also called free GPI, these molecules are not 
attached to either proteins or polysaccharides and are expressed at very high copy 
numbers on both promastigotes and amastigotes surfaces. Leishmania major 
synthesises different type 2 GIPLs consisting of Galf(β1-3)Man(α1-3)Man(α1-4)GlcNH2-
phosphatidylinositol; Gal(α1-3)Galf(β1-3)Man(α1-3)Man(α1-4)GlcNH2-phosphatidyl-
inositol and Gal(α1-6)Gal(α1-3)Galf(β1-3)Man(α1-3)Man(α1-4)GlcNH2-phosphatidyl-
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inositol. These are by convention termed GIPL-1, GIPL-2 and GIPL-3 according to the 
number of galactose residues that they contain. The lipid part generally consists of a sn1-
alkyl-2-acyl-phosphatidylinositol. They were obtained by solvent extractions, purified by 
reverse phase chromatography and analysed by different techniques. 
The GIPLs extracted from wild type Leishmania and ∆glf mutant were first analysed by 
High Performance Thin Layer Chromatography (HPTLC). After separation on a HPTLC-
plate the glycolipids were stained either with the monoclonal antibody MEST-1, an 
antibody directed against terminal Galf of GIPL-1 (Suzuki et al., 2002) or with the 
antibodies L-5-28 and L-5-34 staining GIPL-2 and GIPL-3 (McConville and Bacic, 1989). 
Unfortunately no differences were observed between wild type and mutant. Furthermore 
the staining did not seem to depend on the primary antibodies since incubation of the 
HPTLC plates with only the secondary antibody gave the same pattern. Attempt to adjust 
the concentration of primary and secondary antibodies did not improve the result. 
Moreover as the specificity of L-5-28 and L-5-34 was not clearly defined, these analyses 
were not further pursued. 
 
High performance anion exchange chromatography with pulsed amperometric detection 
(HPAEC) is a simple and convenient technique for monosaccharide analysis. The 
technique relies on the release of monosaccharide from oligosaccharides or 
glycoconjugates by acid hydrolysis and separation at high pH using hydroxide eluents. 
This technique is very sensitive and no sample derivation is needed. However when 
galactofuranose is liberated as a free monosaccharide, it is rapidly converted into the 
thermodynamically favoured galactopyranose form via the open chain of galactose. 
Moreover galactofuranose is acid labile. These problems can be circumvented by the use 
of mild acid methanolysis. This method releases terminal galactofuranose residues in the 
form of methylglycosides in which the reducing oxygen of galactofuranose is covalently 
bonded. Therefore the ring of galactofuranose is locked. Moreover the mild acidic 
condition used for the release preserve the integrity of the monosaccharide. Purified 
GIPLs from Leishmania major wild type and ∆glf mutant were thus subjected to mild acid 
methanolysis and analysed by HPAEC-PAD (Figure 22). The chromatogram obtained 
from wild type shows a small peak eluting at 5.6 min corresponding to methyl-α-
galactofuranose. As methanolysis leads to an inversion of the anomerisation, this result 
is consistent with the presence of terminal β-linked galactofuranose in Leishmania major 
GIPLs. In contrast no peak was noticeable when ∆glf GIPLs were submitted to the same 
analysis indicative of the absence of terminal galactofuranose.  
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Figure 22: Analysis of terminal Galf presence in GIPLs from L. major WT and ∆glf mutant. Galf was 
released from purified GIPLs by mild acid methanolysis and analysed by High pH Anion Exchange 
Chromatography. 
 
Finally GIPLs were analysed by matrix assisted laser desorption ionisation mass 
spectrometry (MALDI-MS) in the negative mode.  As previously mentioned, a sn1-alkyl-2-
acyl-phosphatidylinositol commonly links GIPL-1, GIPL-2 and GIPL-3 to the plasma 
membrane. Because of heterogeneity in the length of the acyl and alkyl chain, 10 distinct 
glycolipids ions can be observed in the negative ion spectrum of Leishmania major wild 
type GIPLs (Figure 23). The ions at m/z 1498.8, 1526.9, 1660.9, 1688.9, 1822.9 and 
1851.0 represent GIPL-1, GIPL-2 and GIPL-3 with C24:0 alkyl and C12:0 or C14:0 acyl 
chains. Additionally, the spectrum presents ions at m/z 1414.7, 1442.8 and 1470.8 
corresponding to GIPL-1 with C18:0 alkyl and C12:0, C14:0 or C16:0 acyl chains 
respectively. These assignments are in agreement with the structures previously 
described in L. major V121 (McConville et al., 1990, Schneider et al., 1994). Interestingly 
GIPL-1 containing a sn1-alkyl-2-lyso-phosphatidylinositol with C24:0 alkyl chain (1316.7) 
is also present in the wild type spectrum. The latter was not reported in L. major V121 but 
seems to be present in L. major Friedlin V1 (Zufferey et al., 2003).  
The negative ion spectrum of GIPLs extracted from GLF/∆glf::PHLEO heterozygous 
mutant was identical to the wild type spectrum (data not shown). In contrast, analysis of 
∆glf mutant revealed the presence of truncated GIPLs. As expected the biosynthesis of 
GIPLs seems to stop after the addition of the second mannose giving rise to GIPLs 
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having the basic structure Man(α1-3)Man(α1-4)GlcNH2-phosphatidylinositol known as 
iM2. The same lipid heterogeneity as seen in wild type GIPLs leads to the observation of 
6 different iM2 peaks at m/z 1154.6, 1252.7, 1280.7, 1308.7, 1336.8 and 1364.8. As a 
result of UDP-Galf absence, LPG biosynthesis is also prematurely stopped leading to the 
accumulation of a residual LPG anchor with the structure Glcα1-PO4-6-Man(α1-
3)Man(α1-4)GlcNH2-sn1-alkyl-2-lyso-phosphatidylinositol. The spectrum is therefore 
dominated by an ion at m/z 1418.6 corresponding to a sodium adduct ([M-2H]2- + Na+) of 
this residual LPG anchor with a C24:0 alkyl chain. The formation of a sodium adduct is 
enabled by the presence of two phosphate groups in this glycolipid. These groups are 
indeed easily ionisable. The molecular ion [M-H]- at m/z 1396.6 corresponds to the same 
residual LPG molecule. Additionally a small amount of truncated LPG anchor with a 
C26:0 alkyl chain can be observed (sodium adduct at m/z 1446.6). The presence of 
these glycolipids indicates that the enzyme involved in glucose phosphate addition does 
not require the prior addition of Galf by LPG1. 
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Figure 23:  MALDI analysis of GIPLs.  The GIPLs from WT and ∆glf mutants were extracted, analysed on a 
MALDI-TOF/TOF spectrometer in the negative mode and the instrument was used at a maximum 
accelerating potential of 20 kV. 
 
All assignments were confirmed by tandem mass spectrometry. Tandem mass 
spectrometry allows indeed the selective determination of individual components within a 
complex mixture. After being selected in the first module of the tandem MS/MS, a 
specific glycolipid is dissociated into fragments that the second module of the apparatus 
can analyse. Some fragmentation pathways are favoured and lead to the obtaining of 
structurally diagnostic ions. A nomenclature system for the designation of fragments ions 
in mass spectra and tandem mass spectra of glycolipids has been introduced and will be 
used here. For glycoconjugates and oligosaccharides, An, Bn, Cn are used for fragments 
that retain the charge on the non reducing end and Xn, Yn , Zn are used for fragments that 
retain the charge on the reducing (lipid) end (Domon and Costello, 1988). Ions related to 
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phosphoric acid (m/z 97, H2PO4- and m/z 79, PO3-) and the (Bn+80), where n is equal to 
the number of sugar rings, dominate the negative ion MS/MS spectra of 
phosphoglycolipids. Moreover cleavage adjacent to the phosphate at the glycosidic bond 
results in an abundant Z0 ion. Additionally, cleavage of the acyl moiety from the 
molecular ion [M-H]- can be observed. The absence of the latter is indicative of a sn1-
alkyl-2-lyso-phosphatidylinositol. All ions observed retain the phosphate group. As 
illustrations, the daughter ions spectra of the molecular ion [M-H]- at 1154.6 m/z  and m/z 
at 1418.6 are presented in Figures 24 and 25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Fragmentation spectra of the molecular ion at m/z 1418.6. GlcN (Glucosamine), Glc 
(Glucose), Ins (Inositol) and Man (Mannose). For clarity the masses have been rounded to their nominal 
values. 
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Figure 25: Fragmentation spectra of the molecular ion [M-H]- at m/z 1154.6. GlcN (Glucosamine), Glc 
(Glucose), Ins (Inositol) and Man (Mannose). For clarity the masses have been rounded to their nominal 
values. 
 
3.3.2.6 Analysis of cell surface expressions of GP63 in ∆glf mutants 
GP63 is a 63 kDa zinc metalloprotease bound by a myristic acid containing GPI-anchor 
to the plasma membrane. It is well expressed on the promastigote stage of Leishmania 
parasites, accounting for 1% of all cellular protein, but is down-regulated in amastigotes. 
As no galactofuranose is present in the GPI-anchor of GP63, the interruption of the 
galactofuranose biosynthesis by GLF gene deletion should not affect the expression of 
this glycoprotein. However GPI-anchors, LPG and GIPLs share some steps of their 
biosynthetic pathway and upregulation of GPI-anchored proteins was already observed 
in some LPG deficient mutants. We thus analysed GP63 expression of Leishmania wild-
type parasites, ∆glf and ∆glf /+GLF mutants by immunofluorescence microscopy and 
western blotting using the monoclonal antibody GP63-235, that recognises specifically L. 
major surface protease GP63 (a generous gift of W. Robert McMaster, Vancouver, 
Canada). For immunofluorescence microscopy, Leishmania promastigotes of wild type, 
homozygous mutants (∆glf/) and add back (∆glf/ + GLF) were immobilised on cover 
slides and stained with GP63-235 antibody and a Cy3-coupled secondary antibody. 
Western blot analysis was performed as described previously for LPG analysis. The 
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immunoblot was stained with a 1:50 dilution of a hybridoma culture supernatant of GP63-
235 antibody and signals detected by an enhanced chemiluminescence (ECL) system. 
No differences of GP63 expression on Leishmania wild type, ∆glf- and ∆glf-/ + GLF 
mutants could be detected neither in the immunofluorescence nor in the western blot 
analysis (Figure 26 and 27).  
 
 
 
 
 
Figure 26: Detection of GP63 on the cell surface of L.major WT, ∆glf- and ∆glf-/+GLF. The parasites 
were fixed on poly (L) lysine coated coverslips and incubated with monoclonal antibody GP63-235 and Cy3 
coupled secondary antibody. Nuclei and kinetoplast were stained with DAPI. 
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Figure 27: Deletion of GLF does not affect GP63 expression. a) Western Blot analysis. Parasites from L. 
major WT, ∆glf and ∆glf-/+GLF  were extracted and separated on a ProSieve SDS Page and Western 
Blotting with anti – GP63 antibody. b) To confirm equal loading a second gel was stained with Commassie 
Blue. 
 
3.4 Cellular localisation of UGM 
The analysis of the UGM amino acid sequence revealed no known signal sequences for 
membrane association or anchorage suggesting that the UGM is soluble. To confirm this 
finding, the cellular localisation of UGM was examined using episomal expression of N-
terminal GFP-tagged protein (GFP::GLF) in wild type L. major or in the ∆glf null mutant. 
The green fluorescent protein (GFP) of Aequorea victoria has been introduced as a 
convenient marker in eukaryotic organisms including L. major for localisation of 
engineered fusion proteins (Chalfie et al., 1994; Ha et al., 1996). To generate the N-
terminal GFP tagged UGM, the full length open reading frame lacking start codon was 
PCR amplified and cloned in the sense orientation into the BamH I site of pXG-GFP+2. 
10 µg of the resulting plasmid pXG-GFP+2-GLF were transfected in the ∆glf mutant. As a 
control L. major wild type cells were transfected with a plasmid expressing GFP (pXG-
GFP+). LPG that is absent from ∆glf mutant was re-expressed after transfection with a 
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plasmid containing GFP::GLF, demonstrating that the GFP tagged protein is 
enzymatically active (data not shown). Fluorescence microscopy showed that the GFP 
tagged UGM is distributed throughout the whole cell within L. major wild-type (Figure 28) 
and ∆glf mutant supporting the cytoplasmic location of UGM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Expression of GFP tagged UGM in  L. major. A N-terminal GFP tagged UGM (pXG-GFP+2-
UGM)  was transfected in the  ∆glf  mutants. L. major wild-type was electroporated with pXG-GFP+ (B2863). 
The cells were fixed  with 4% paraformaldehyde on a poly-L-lysine coated coverslips. An additionally DAPI 
staining was performed. 
 
3.5 Experimental mice infection study with ∆glf mutant 
To investigate the participitation of the GLF gene in infectivity, a mouse infection model 
was used. First, as Leishmania loose virulence in culture, the parental wild type strain, 
the homozygous (∆glf) and the corresponding add back mutant (∆glf/+GLF) were passed 
once through mice to optimise the virulence of the parasites. For this purpose, all 
parasites were grown to late logarithmic phase to enrich the population of infectious 
metacyclic promastigotes and 1 x 107 parasites per mouse were injected in the hind left 
footpad. After 10 days, amastigotes were re-extracted from lymph nodes, transferred to 
liquid media at 27°C and cultured to allow re-differentiation into promastigotes. 
Importantly all re-isolated parasites were kept in culture for less than three passages 
before inoculation into mice. These freshly isolated parasites were grown to late 
logarithmic phase and 2 x 106 parasites per mouse were injected in the hind left footpad. 
The size of the lesion was measured weekly over a 10 weeks period by comparing of the 
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thickness of the infected and non infected hind footpad using a Vernier calliper (Figure 
29). After four weeks, lesion were clearly visible in all mice infected with the parental wild 
type strain, while lesion formation was slightly delayed in mice injected with the add 
backs mutant. In contrast no lesion development was observed in mice that were 
inoculated with the ∆glf mutant (Figure 30) showing that the UGM is an important 
virulence factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Infection of Balb/c mice with wild type and ∆glf mutant. Balb/c mice were fixed (A) and 
infected with 2 x 106 wild type parasites, homozygous mutant and add back. (B) Lesion formation of 
Leishmania wild type parasites 11 weeks post infection. (C) The size of the lesion was determined using a 
Vernier calliper (C) comparing infected and non infected hind footpad (D). 
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Figure 30: In vivo testing of virulence. The time course of lesion formation after infection of Balb/c mice 
with L. major wild type (blue line), homozygous mutant (red line) and the corresponding add back (green line) 
mutant strains were monitored by measuring the swelling footpad. The median size differences of the 
infected and the non infected hind footpad are plotted against the weeks post infection. For each clone, four 
animals were infected. 
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4 Discussion  
The surface glycoconjugates, that forms a dense cell surface glycocalyx (Pimenta et al., 
1991, Garami and Ilg, 2001), comprised of GPI-anchored glycoproteins, 
lipophosphoglycan (LPG), free GPI glycolipids (GIPLs) and proteophosphoglycans 
(PPGs) are essential for the survival and virulence of Leishmania parasites (McConville, 
2002, Descoteaux et al., 1999). Hence some enzymes involved in their biosynthetic 
pathways might provide interesting drug targets. Because of its absence in human, the 
UDP-galactopyranose mutase (UGM) represents an attractive candidate. This enzyme, 
encoded by the GLF gene, is responsible for the interconversion of the activated UDP-
galactopyranose and UDP-galactofuranose, and represents thus a central enzyme in 
galactofuranose biosynthesis. Moreover it is essential for the survival or virulence of 
various pathogenic bacteria. Although in eukaryotes the existence of such an enzyme 
was since long suspected, it had so far not been identified. Here we report the 
characterisation of Leishmania UGM and determine its role in glycoconjugate 
biosynthesis and importance for parasite virulence, by a targeted gene deletion 
approach.  
 
4.1 Identification and partial characterisation of L. major UDP-
galactopyranose mutase 
The existence of an enzyme converting UDP-Galp into UDP-Galf was suggested by the 
early work of Trejo and colleagues in fungi (Trejo et al., 1970). Nevertheless the genes 
encoding this enzyme (GLFs) were the only enzymes involved in the Galf metabolism 
identified in bacteria (Nassau et al., 1996; Weston et al., 1997; Koplin et al., 1997). In 
order to identify GLFs from eukaryotic pathogens, blast searches of Leishmania major 
genome with prokaryotic GLFs were conducted. Particular attention was paid to the 
presence of a flavin binding domain in the candidates, since flavin is essential for the 
catalytic activity of prokaryotic UGMs (Sanders et al., 2001). Moreover the phylogenetic 
distribution of the gene, specifically its occurrence in fungi and protozoa known to 
synthesise Galf in comparison to taxa lacking Galf, was used as additional selection 
criterion. A single L. major candidate gene encoding a 491 amino-acid protein with low 
homology to prokaryote UGMs was identified. Importantly, this protein was conserved in 
various eukaryotes known to express Galf such as Aspergillus fumigatus and 
Trypanosoma cruzi but was absent from Drosophila melanogaster, Arabidopsis thaliana, 
yeast and mammals, where Galf has never been found.  
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Direct evidence that the selected genes encoded active UGMs was provided by an in 
vivo complementation assay for UDP- Galf synthesis in E.coli. This system was based on 
the expression of Klebsiella pneumoniae LPS O-antigen (that contains Galf) in a strain of 
E. coli deleted for the endogenous LPS rfb locus. Inactivation of Klebsiella GLF 
abrogated LPS biosynthesis, but could be rescued by episomal expression of our 
candidate genes. Activity of the enzymes was then confirmed by an in vitro enzymatic 
assay. The same approach was used by Beverley and co-workers who independently 
reported the characterisation of some eukaryotic UGMs at the same time that we did 
(Beverley et al., 2005; Bakker et al., 2005).  
Despite the extensive divergence, eukaryotic UGMs share key properties with those of 
prokaryotes. The eukaryotic UGMs show the characteristic dinucleotide binding motif of 
the glutathione reductase structural family (Dym and Eisenberg, 2001; Wierenga et al., 
1983) and importantly most of the residues involved in UDP Galp binding were 
conserved. Considering the low homology between bacterial and eukaryotic UGMs, the 
conservation of many residues of the binding site is intriguing and the crystal structure 
should be solved to determine if the shape of the UDP-Gal binding site is conserved. 
However preliminary tests of a panel of prospective prokaryotic UGM inhibitors suggest 
that they fail to inhibit eukaryotic UGMs (Beverley et al., 2005). Thus it might be 
necessary to develop eukaryotic specific UGM inhibitors in the future. 
As in prokaryotes, eukaryotic UGMs lack signals typical for membrane association or 
anchorage and are likely to be cytoplasmic. However, there is precedent in other 
systems for the compartmentalisation of proteins involved in nucleotide sugar 
interconvertion (Griffith et al., 2004; Pattathil et al., 2005). Thus cellular localisation of 
UGM was examined using episomal expression of N-terminal GFP-tagged protein 
(GFP::GLF) in Leishmania major. The GFP tagged UGM is distributed throughout the 
whole cell supporting the cytoplasmic localisation of UGM. This implies that UDP- Galf is 
synthesised in the cytoplasm, like most nucleotide sugars, and strongly suggests the 
existence of an UDP-Galf transporter able to provide substrate to the 
galactofuranosyltransferases located within the Golgi apparatus (Späth et al., 2000).  
 
Interestingly a number of genes with strong homology to GLFs were found in lower 
eukaryotes not known to synthesise Galf. The predicted proteins show also conservation 
of key residues involved in cofactor and substrate binding. Most of them have probably 
UGM activity as well. Thus Galf synthesis seems to occur more widely than previously 
thought and would be found in various pathogens of humans, animals and plants. 
Amongst organisms that presumably synthesise Galf, we could cite the human 
nematodes parasites Brugia and Onchorcerca. 
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4.2 Generation and characterisation of a L. major GLF gene 
deletion mutant 
The targeted gene deletion strategy was determined by the genetic organisation of the 
parasite. The genome of Leishmania does not contain any introns and the transcription 
takes place in a polycistronic fashion. The polycistronic pre-mRNAs are further 
processed by coupled trans-splicing and polyadenylation reactions to generate mature 
monocistronic mRNAs. (Stiles et al., 1999, Stein et al., 1990). Gene expression is not 
directed by promoters (or at least these have not yet been identified) but by sequences 
present in the 3´and 5´flanking region. Thus each of the two GLF alleles was precisely 
replaced by the coding sequence of an antibiotic resistant gene, leaving the 3’ and the 5’ 
flanking regions completely unaltered to ensure correct expression of the markers. For 
this purpose targeting constructs were prepared by homologous recombination in 
bacteria (Zhang et al., 2000). Interestingly, the integration of the hygromycin resistance 
gene was preferred over the phleomycin resistance gene. The latter is a small gene 
encoded by a 373 bp region, while hygromycin and GLF are encoded by 1026 and 1473 
bp respectively. The size of the DNA might influence the homologous recombination or 
the polycistronic gene transcription. In Leishmania parasites, targeted gene replacement 
is extremely influenced by the amount and quality of DNA. High amounts of the targeted 
gene deletion constructs resulted in multiple false insertions into the genome. This 
phenomenon was previously reported by Cruz et al. (1990 and 1991). GLF gene deletion 
and the correct insertion of the antibiotic resistant markers were confirmed by southern 
blot. For comparison of the results, the parental wild type strain was treated and 
cultivated in the same way as the mutants. Moreover several clones were analysed in all 
experiments. 
  
4.2.1 Characterisation of L. major GLF gene deletion mutants 
As no other GLF homologous was found in the L. major genome, no alternative pathway 
for galactofuranose should exist and the mutants were expected to lack any Galf.  
The clones obtained after two rounds of targeting gene deletion were viable, 
demonstrating that GLF is not essential for the survival of Leishmania parasites under in 
vitro conditions. Moreover all mutants analysed in this study grew as well as the parental 
strain of Leishmania major. In Mycobacteria, GLF deletion is lethal. However, the role of 
Galf in the survival or virulence of bacteria depends greatly of its abundance and position 
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in the glycoconjugates. Galactofuranose is indeed an inner component of the 
mycobacterial cell wall and is hence necessary for its integrity. In Leishmania 
promastigotes (insect stage), Galf occupies a similar position in the anchor of the 
abundant polysaccharide LPG. Consequently GLF deletion is expected to affect 
profoundly the glycocalyx. However, in the amastigotes (stage of the parasite in the 
mammalian host), LPG is down regulated and the glycocalyx almost absent. Thus these 
changes were not expected to influence Leishmania survival in vitro. Moreover various 
mutants deficient in LPG and/or other glycoconjugates have been described and are 
perfectly viable ( Späth et al., 2000 and 2003, Zufferey et al., 2003). 
In Leishmania major, galactofuranose is not only present in the GPI-anchor of LPG, but 
also in the main surface Glycosylinositolphospholipids (GIPLs). Thus in addition to the 
loss of LPG, deletion of GLF should result in truncated GIPLs because Galf occupies the 
terminal, penultimate or antepenultimate position in these glycoconjugates. On the other 
hand, the synthesis of other molecules should not been altered. In order to confirm these 
predictions, the expression and structure of cell surface glycoconjugates was carefully 
analysed. The complete absence of LPG was observed by Western blotting using the 
monoclonal antibody WIC 79.3 directed against the galactose substituted repeating unit 
characteristic of L. major LPG and PPGs. Although the membrane bound PPGs and the 
newly synthesised PPGs accumulating in the flagellar pocket before secretion should 
weakly stain the parasite, no signal could be detected. Further experiments confirmed 
that unexpectedly L. major MHOM/SU/73/5ASKH expresses low level of PPGs. The 
absence of membrane bound PPGs was already reported in Leishmania major LV39 
(Späth et al., 2000) but the quasi absence of mucin-like PPGs is more surprising. The 
PPGs profiles are known to vary markedly in different Leishmania species and 
developmental stages. L. major secretes much fewer PPGs than Leishmania mexicana. 
Given the paucity of information on PPGs expression in different strains of Leishmania, it 
can only be speculated that different Leishmania strains vary in their glycoconjugates 
expression. By heterologous expression of secreted acid phosphatase, it was however 
demonstrated that the PPG biosynthetic machinery is intact in the ∆glf mutant. In these 
conditions, an increased phosphoglycosylation is even observed in the mutant. Such 
increase is a logic consequence of the absence of LPG backbone synthesis and was 
previously reported in another LPG deficient mutant (Zufferey et al., 2003).  
 
In order to further characterise the ∆glf mutants, the structure of the GIPLs was 
intensively investigated. The GIPLs were extracted, purified by reverse phase 
chromatography and analysed by Matrix Assisted Laser Desorption Ionisation Mass 
spectrometry (MALDI-MS) and tandem mass spectrometry (MALDI-MS/MS). Like other 
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strains of L. major analysed to date, L. major MHOM/SU/73/5ASKH expresses only type 
2 GIPLs. The structures of the glycan and lipid moieties deducted from our analyses are 
in perfect agreement with previous reports (McConville et al., 1990, Zuffery et al., 2003). 
As expected, the biosynthesis of GIPLs is interrupted after the addition of the second 
mannose in the GLF null mutant resulting in truncated GIPLs deficient in Galf. In addition 
accumulation of the residual LPG anchor was observed. This residual anchor can be 
distinguished from GIPLs by the presence of a glucose phosphate residue located on the 
terminal mannose and a sn1- alkyl-2-lyso-phosphatidylinositol. 
The early steps in GIPLs and LPG anchor biosynthesis are the same as those involved in 
protein anchor biosynthesis involving the transfer of N-acetylglucosamine to sn1-alkyl sn-
2-acyl phosphatidylinositol, followed by de-N-acetylation and transfer of a mannose 
residue to form Manα1-4GlcN-PI. The first committed step for the GIPLs type 2 as for the 
LPG is the addition of the mannose residue in a α 1-3 linkage to this intermediate. 
Galactofuranose is added to this α 1-3 linked mannose residue. The existence of two 
different galactofuranosyltransferases involved either in the LPG anchor or in the GIPLs 
biosynthetic pathways was suggested by deletion of LPG1 gene encoding the putative 
galactofuranosyltransferase that abolished Galf addition to the LPG anchor but not to the 
GIPLs. The remaining steps in LPG anchor include the addition of two more galactose 
residues, one glucose phosphate residue and deacylation of the lipid moiety. However 
the ordering and enzymology of these reactions has not been elucidated. The presence 
of glucose phosphate in the residual LPG core of the ∆glf mutant indicates however that 
addition of this residue does not require the prior addition of Galf by LPG1. Interestingly 
the amount of truncated GIPLs with a C24:0 alkyl and a C12:0 or C14: acyl chain is not 
abundant in the ∆glf mutant, although these two phosphatidylinositols are the main lipids 
found in wild type GIPLs. GIPLs biosynthesis requires remodelling of the sn-2 fatty acid 
before transport to the plasma membrane but remodelling of the alkyl chain has never 
been described. Therefore in absence of galactofuranose addition, GIPLs precursors 
with long alkyl chains seem to be directed towards LPG biosynthesis. This suggests a 
competition between the GIPLs specific galactofuranosyltransferase and the enzymes 
specifically involved in LPG synthesis (eg. glucose phosphate transferase, deacylase, 
LPG1). The differential expression of these enzymes could thus account for the selective 
down regulation of LPG in the amastigote stage which is a crucial step for survival of 
Leishmania in the mammal host. 
 
As just mentioned the biosynthetic pathway of protein anchors is closely linked to those 
of LPG and GIPLs. Therefore although GPI-anchors of proteins do not contain any Galf, 
their expression was investigated by indirect immunofluorescence and Western blotting 
                                                                                                                Discussion 
 81
using the antibody GP63-235 directed against the metalloprotease GP63. Expression of 
GP63 was not affected in the ∆glf mutant. Thus as predicted the ∆glf mutant lacks LPG 
and expresses truncated GIPLs whereas the biosynthetic machinery of other 
glycoconjugates is unaffected. 
 
4.2.2 Virulence  
The characterised ∆glf mutant was used to elucidate the role of Galf in parasite virulence 
and therefore assess if UGM is a potential drug target. The virulence of the ∆glf mutant 
was assessed by lesion formation of Balb/c mice after inoculation with the parasites. 
Because Leishmania parasites loose virulence in culture, all parasite lines were passed 
through mouse at high inoculating dose, re-isolated and maintained for less than 3 
passages in vitro prior to virulence testing. Remarkably mice inoculated with the ∆glf 
mutant did not develop any lesion while in contrast mice infected with the wild type strain 
and “addback” line showed rapid disease progression. As Galf is present in the anchor of 
LPG and this molecule is a known virulence factor in L. major, a decrease of virulence 
was expected. However, in contrast to Leishmania major ∆lpg1 mutant that lacks 
exclusively LPG and shows a delayed disease progression, the ∆glf mutant seems 
completely avirulent. This virulence phenotype could be attributed to the simultaneous 
loss of LPG and Galf in GIPLs. However it is difficult to determine the role of GIPLs in 
pathogenesis. Indeed the structural homology and the sharing of biosynthetic pathways 
with LPG and GPI-anchored proteins (McConville and Ferguson 1993, McConville et al., 
2002) preclude the obtaining of mutant exclusively deficient in GIPLs. Thus genetic 
studies that attempted to assign a specific role to GIPLs yielded contradictory results 
(Ilgoutz et al., 1999; Mensa- Wilmot et al., 1999, Garami and Ilg 2001). Nevertheless the 
ability of purified GIPLs to inhibit protein kinase C activity and nitric oxide production 
implicated them in parasite survival in macrophages. Though, these properties are 
associated with the lipid part of GIPLs and should not be affected in the ∆glf mutant. 
Additionally GIPLs containing a terminal Galf residue have been implicated in the 
interaction of L. major with macrophage (Suzuki et al., 2002). However the L. major 
∆ads1 mutant that lacks all ether lipids including LPG and GIPLs recently counteracted 
all these proposals. Indeed this mutant only exhibits a reduction of virulence similar to 
lpg1- and is able to enter macrophages as well as wild type parasites. Preliminary 
experiments indicate that promastigotes of the ∆glf mutant are able to enter 
macrophages as efficiently as the parental strain and in this respect behave similarly as 
the ads1- mutant. However the interaction promastigote-macrophage might not be 
relevant as the first cell interacting with Leishmania promastigotes seems to be 
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polymorphonuclear neutrophils (PMN). Interestingly the infectivity of ∆glf mutant toward 
PMN seems reduced. Additional experiments to study the infectivity of ∆glf 
promastigotes and amastigotes toward PMN and macrophages are required to determine 
the role of galactofuranose in macrophage invasion and parasite replication inside 
macrophages. It should be emphasised that LPG is absent from the intracellular 
amastigote stage of the parasite and thus in contrast to all other existing mutants, ∆glf 
amastigotes have an exclusive defect in GIPLs. 
Unexpectedly MHOM/SU/73/5ASKH expresses low level of PPGs and thus the ∆glf 
mutant resembles the ∆lpg2 mutant, an avirulent mutant deficient in LPG and PPGs. The 
loss of virulence observed after deletion of GLF could thus be due to a fortuitous choice 
of L. major strain and be attributed to the concomitant absence of LPG and PPGs. Over 
the last decade, researchers tried to determine the glycoconjugate responsible for 
virulence of Leishmania. However, there seems to be a certain level of functional 
redundancy between the different surface glycoconjugates of Leishmania and thus loss 
of virulence is generally associated with the absence of several glycoconjugates. 
Moreover, it is now acknowledged that different species of Leishmania rely differently on 
their surface glycoconjugates for virulence (Turco et al., 2001). Differences between 
strains have also been suggested in the case of L. mexicana. Indeed the deletion of 
dolichol-phosphate-mannose synthase gene resulted in a mutant that lack all GPI-
anchored molecules while attempts to delete the same gene in another strain of L. 
mexicana were unsuccessful. In L. major, however, most studies highlighting the roles of 
glycoconjugates have been conducted with the same strain. The present work shows 
that differences in glycoconjugates expression are found between different strains. These 
might be reflected by the degree of virulence of each strain and account for some of the 
inconsistency found in literature.  
The study presented in this thesis highlights the essential role of galactofuranose for L. 
major virulence and provides encouraging results for the chemotherapeutical potential of 
Galf metabolism in Leishmania major. Although this role cannot be extrapolated to other 
species of Leishmania, it might not be restricted to L. major. Indeed a recent study 
suggested that galactofuranose containing GIPLs are important for basic survival of 
Trypanosoma cruzi (MacRae et al., 2006). In this respect, the identification of eukaryotic 
UGMs represents an important step that allows studying the requirement of Galf for the 
viability or pathogenicity of different organisms. Such study with the opportunistic fungus 
Aspergillus fumigatus indicates an important contribution of Galf to the virulence of this 
pathogen. An inhibitor of eukaryotic UGM might thus be active against a wide range of 
pathogens.  
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6 Appendix 
6.1 Map of pXG: Leishmania expression vector with NEO marker 
 
 
 
 
 
 
 
 
 
In the vectors of pXG-serie, the expression of the gene is driven by a Leishmania 
intergenic region providing signals for trans-splicing and polyadenylation.  This intergenic 
region flanks the unique polylinker SmaI or BamHI sites. Insertion of ORF into these sites 
gives high level of expression, fairly constant through parasite life cycle (log, stationary 
phase promastigotes; lesion amastigotes) (Ha et al., 1996; Chakkalath et al. 2000). This 
vector contains all genetic information required for expression and replication in 
Leishmania. It is originated from a circular 30Kb region bearing the dihydrofolate 
reductase thymidylate synthase gene amplified in certain methotrexate resistant 
Leishmania.   
Any site in the vector (compatible with marker function) can be used for shuttle vector 
purposes. The NEO gene is originally from pR-NEO (Kapler et al. 1990) 
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6.2 Map of pXG –GFP+: Leishmania GFP vector 
 
 
 
 
 
 
 
 
 
The pXG-GFP+ vector contains a modified GFP called “GFP+” (GC rich; S56T mutation) 
inserted into expression site of pXG (Ha et al., 1996). 
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6.3 Map of pXG –GFP+2: Leishmania vector for making 
N- terminal GFP fusions to protein 
 
 
 
 
 
 
 
 
 
Gene fusions may be made conveniently by inserting a gene in the appropriate reading 
frame in the polylinker located 3’-ward of the GFP+2 gene. The GFP+2 gene is a GFP 
variant similar to GFP+; it contains GC-rich codons as well as mutations that improve the 
fluorescence signal (L64T65), making it suitable for ‘fluorescein’-oriented fluorescence 
optics (Ha et al., 1996).   
In the map the blue bars represent ORFs, red arrows indicated mRNAs known or 
predicted from the L. major intergenic regions. All derived from regions surrounding the 
DHFR-TS gene. 
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7 Abbreviations 
°C degree Celsius 
µm micrometer 
µl microliter 
α− Anti- 
ABTS  2,2’-Azino-di-(3-ethylenbethiazolin-sulphate) 
A. fumigatus Aspergillus fumigatus 
AP Alkaline phosphatase 
APS Ammonium peroxidisulphate 
Ara arabinose 
ATP Adenosine triphosphate 
BCA  Bichionic acid 
BCIP  5-Brom-4-chlor-3-indolyl-phosphate 
bp Base pairs 
BSA Bovine serum albumin 
CMP Cytidine 5’-monophosphat 
Da Dalton 
DAPI 4’,6-Diamedino-2-phenylindol 
DMEM ‘Dulbecco’s Modified Eagle’s medium’ 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DTT Dithiothreito 
E. coli Escherichia coli 
EDTA Ethylendiamine-N,N,N’,N’-tetraacetic acid 
e.g. exempli gratia 
ELISA Enzyme linked immono sorbant assay 
et al.  et alii 
EtN ethanolamine 
Fig. figure 
Gal galactose 
Galf galactofuranose 
Galp galactopyranose 
GFP Green fluorescent protein 
GIPLs Glycosylinositolphospholipids 
GlcN Glucosamine 
Glc Glucose 
GP63 glycoprotein 63 
GPI Glycosylphosphatidylinositol  
h hours 
hyg hygomycin 
Ins Inositol 
kb kilobase 
kDa kilodalton 
K. pneumoniae Klebsiella pneumoniae 
L. Leishmania 
L.major/mexicana/donovani Leishmania major/mexicana/donovani 
LB Luria-Bertani  
LPG Lipophosphoglycan 
LPS Lipopolysaccharide 
M Molar 
mM millimolar 
mAb Monoclonal antibody 
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MALDI-MS Matrix Assisted Laser Desorption Ionisation Mass 
spectrometry 
Man mannose 
min minutes 
ml millilitre 
mm millimeter 
NBT Nitrotetrazolium-blue chloride 
NCAM Neural cell adhesion molelcule 
neo neomycin 
OD Optical density 
P phosphate 
PAGE Polyacrylamide gelelectrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
phleo phleomycin 
PI phosphatidylinositol 
PMSF Phenylmethansulfonylflouride 
PPG Proteophosphoglycan 
RT Room temperature 
SAP secreted acid phosphatase 
SDS Sodium dodecyl-sulphate 
sec seconds 
TEMED  N,N,N’,N’-Tetramethyl-ethylendiamin 
TRIS  Tris(hydroxymethyl)-aminomethan) 
UDP Uridin 5’-diphosphate 
UGM UDP-galactopyranose mutase 
UTR untranslated region 
wpi weeks post infection 
z.B. zum Beispiel 
 
 
 
                                                                                        Curriculum Vitae und Publikationsliste                        
                                                                                                                                                  97
 
Curriculum Vitae  
 
Name  Barbara Kleczka 
Adresse 
 
 
 Am Listholze 11 
30177 Hannover 
E-mail  
  
 Kleczka.Barbara@mh-hannover.de 
Geburtsdatum, -ort 
  
 13.01.1978, Hannover 
Staatangehörigkeit  Deutsch 
 
 
Schule 
 
1984-1988  Friederich-Ebert Schule Langenhagen (Grundschule) 
1988-1990  Orientierungsstufe Langenhagen 
1990-1997  Gymnasium Langenhagen 
Juni 1997  Abitur 
 
 
Hochschulstudium 
 
Okt.1997 – März 1998 
 
April 1998 – Sept.1999
 
 
August 1999  
 
 
 
 
Okt.1999- März 2003 
 
 
 
April 2001- Juni 2001 
 Biologie-Studium an der Universität Osnabrück 
 
Grundstudium der  Biologie an der Universität Hannover 
 
 
Vordiplom 
Schwerpunkte:  Botanik, Chemie, Genetik, Mikrobiologie, Physik und Zoologie 
 
 
Hauptsstudium Biologie 
Schwerpunkte: Zoologie, Mikrobiologie, Versuchstierkunde 
 
Hilfswissenschaftliche Angestellte im „Zoologischen 
Grundpraktikum für Tiermediziner“ 
 
April 2002 – Dez. 2002
 
 
 
 
 
 
 
März. 2003 
 
 Diplomarbeit im Fachgebiet Fischkrankheiten und Fischhaltung, 
Arbeitsgruppe Dieter Steinhagen, Tierärztliche Hochschule 
Hannover 
Thema: „Untersuchungen an inflammatorischen Zellen aus 
Karpfen mit einer Trypanoplasma borreli-Infektion“ 
 
 
Diplom (Note:1,3) 
 
 
 
 
                                                                                        Curriculum Vitae und Publikationsliste                        
                                                                                                                                                  98
 
Promotion 
 
Jun. 2003  Beginn der Promotion in der Arbeitsgruppe von Prof. Rita 
Gerardy-Schahn, Abteilung Zelluläre Chemie, Zentrum 
Biochemie, Medizinische Hochschule Hannover  
Thema der Promotion: “Cloning, Functional Characterisation 
and Deletion of UDP-Galactopyranose Mutase of Leishmania 
major” 
 
Jul. 2006  Abschluss der Promotion mit dem Hochschulgrad Dr. rer. nat. 
mit magna cum laude an der Naturwissenschaftlichen Fakultät 
der Gottfried Wilhelm Leibniz Universität Hannover 
  
 
Publikationsliste 
 
Wissenschaftliche Veröffentlichungen: 
 
Bakker H., Kleczka B., Gerardy-Schahn R., Routier F.H. (2005). Identification and partial 
characterisation of two eukaryotic UDP-galactopyranose mutases. Biol. Chem. 386 (7), 657-
661 
 
Posterpräsentationen: 
 
20.11.2003-22.11.2003 
14th Joint Meeting 2005 of the ‘Studiengruppe Glykobiologie der Gesellschaft für Biochemie 
und Molekularbiologie’, the ‘Netherlands Society for Glycobiology’ and the ‘Groupe Lillois de 
Glycobiologie’, Lille, France 
Topic: ‘Leishmania major UDP-galactopyranose mutase: characterisation and validation of a 
potential drug target’, Kleczka B., Bakker H., Gerardy-Schahn R., Routier F.H. 
 
17.11.2004-20.11.2004 
Joint Meeting of the Society for Glycobiology and the Japanese Society of Carbohydrate 
Research, Honolulu, USA 
Topic: ‘Leishmania major UDP-galactopyranose mutase: characterisation and validation of a 
potential drug target’, Kleczka B., Lamerz A.C., Bakker H., Wiese M., Gerardy-Schahn R., 
Routier F.H. 
 
04.09.2005- 09.09.2005 
XVIII International Symposium on Glycoconjugates, Firenze, Italy 
Topic:’ Identification and functional characterisation of a UDP-Glucose Pyrophosphorylase 
from Leishmania major’, Lamerz A.C., Kleczka B., Wiese M., Routier F.H., Gerardy-Schahn 
R. 
 
27.10.2005- 29.10.2005 
16th Joint Meeting 2005 of the ‘Studiengruppe Glykobiologie der GBM’, the ‘Netherlands 
Society for Glycobiology’, the ‘Groupe Lillois de Glycobiologie’ and the ‘Belgian Working 
Group for Glycoscience’, Hannover, Germany 
Topic: ‘Characterisation of a Leishmania major UDP-Galactopyranose Mutase gene deletion 
mutant’, Kleczka B., Lamerz A.C.,  Van Zandbergen G., Laskay T., Solbach W., Bakker H., 
Wiese M., Gerardy-Schahn R., Routier F.H. 
Topic: ‘Leishmania major UDP-Glucose pyrophosphorylase: identification, characterisation 
and analysis of a gene deletion mutant’ Lamerz A.C., Kleczka B., Wiese M., Routier F.H., 
Gerardy-Schahn R. 
 
                                                                                                                  Erklärung 
 99
 
9  Erklärung 
 
Hiermit versichere ich an Eides statt, dass ich die vorliegende Dissertation selbständig 
und nur unter Verwendung der angegebenen Quellen und Hilfsmittel angefertigt habe. 
Außerdem versichere ich an Eides statt, dass die zugrunde liegenden Ergebnisse nicht 
für eine andere Prüfungsarbeit verwendet worden sind. 
 
 
Hannover, 31.05.2006 
 
                                                                                                                       Danke 
 100
10 Danksagung 
Hiermit möchte ich mich bei all denen bedanken, die mich während meiner Doktorarbeit 
tatkräftig unterstützt haben und immer für mich da waren: 
 
Frau Prof. Rita Gerardy-Schahn danke ich für die herzliche Aufnahme in Ihre Gruppe. 
Ihre uneingeschränkte Unterstützung und Förderung haben zum wesentlichen Gelingen 
dieser Arbeit beigetragen. 
.  
Frau Prof. Françoise Routier danke ich herzlich für die Betreuung während meiner 
Doktorarbeit, für die tatkräftige Unterstützung dieser Studie, für das umfangreiche 
Korrekturlesen und Ausmerzen umständlicher Formulierungen in dieser Arbeit. 
 
Ein besonderer Dank geht an Dr. Anne Lamerz (Sid) für Ihre selbstlose Unterstützung in 
den Leishmanien Arbeiten, für die lebhaften Diskussionen, für Ihre Adleraugen, für Ihre 
Motivation und dafür, dass sie immer für mich da war und zu einer meiner besten 
Freundinnen geworden ist. 
 
Herrn Prof. Dieter Steinhagen danke ich ganz herzlich für die Übernahme des 
Korreferates. 
 
Dr. Hans Bakker danke ich für sein Interesse am Projekt, die vielen Tipps und 
Anregungen im Laboraltag.  
 
Dipl. Biochem. Anita Stolz danke ich für die Einführung in die Massenspektrometrie, für 
Ihre lebensfrohe und spontane Art, ihre Freundschaft, die vielen guten Gespräche und 
den vielen Spaß, den wir hatten. 
 
Herrn Dr. Wiese danke ich für die Bereitstellung von Arbeitsmöglichkeiten und für die 
Zusammenarbeit für die Erzeugung von Deletionsmutanten in Leishmanien. Ger van 
Zandbergen und Alexander Wenzel danke ich für die Durchführung der 
Mausinfektionsstudien. 
 
Monika Berger, Ulrike Bernard, Andrea Bethe, Hannelore Burkhardt, Bodo Diercks, 
Melanie Grove, Evelin Herzog, Astrid Oberbeck, Brigitte Philippens und Daniela 
Wittenberg danke ich für die exzellente technische und organisatorische Unterstützung 
im Labor. 
 
Für eine äußerst nette Laboratmosphäre, die vielen lustigen Gespräche (besonders 
Freitags), für die vielen Kekse und Kuchen, die unvergesslichen Kongresse und dafür, 
dass sie mich immer zum Lachen gebracht haben, bedanke ich mich ganz herzlich bei 
Angel Ashikov, Anne Bergfeld, Sebastian Damerow, Friedrich Freiberger, Jutta Fuhlrott, 
Almut Günzel, Herbert Hildebrand, (Keks-) Roland Kabuß, Martina Mühlenhoff, Anja 
Münster-Kühnel, Imke Oltmann-Norden, Melanie Oschlies, Valentina Ritz-Sedlacek, Iris 
Röckle, Philip Schmarlhorst, David Schwarzer, Katharina Stummeyer und Birgit 
Weinhold. 
 
Ein großes Dankeschön geht an Christa Zeigner für die Unterstützung bei allen offiziellen 
Angelegenheiten und für ihre lustige Art. 
 
 
 
 
                                                                                                                       Danke 
 101
Ganz besonders bedanken möchte ich mich bei meinen besten Freundinnen Annika 
Herwig und Esther Lipokatic-Takacs. Danke, dass Ihr immer für mich da gewesen seid, 
für die schöne Studienzeit, die wir zusammen verbracht haben, für die vielen guten und 
hilfreichen Gespräche, und für die unvergesslichen Aktionen, an die wir bestimmt öfters 
zurückdenken werden.  
 
Maria und Uli danke ich für die Aufmunterungen und die vielen kulinarischen Abende. 
 
Ein großes Dankeschön geht an Moni und Uwe Klausmeyer für Ihre unglaubliche Liebe 
und Unterstützung, ohne die ich nicht dort wäre wo ich heute bin. 
 
Ganz besonders möchte ich mich bei meiner Familie bedanken, die mir immer einen 
starken Rückhalt gegeben hat, jederzeit für mich da war, mir zur Seite standen und mich 
immer unterstützt haben: Carmen, Marco, Sturmi, Isabell, Matthias, Sophie, Lena,  
Simone, Jörg, Mitja, Sascha, Nicola, Christian, Joje, Bena und Hildegard. Danke, dass 
es Euch gibt und ich bin verdammt froh, dass ich Euch habe. 
 
Zuletzt möchte ich mich bei Martin, dem wichtigsten Menschen in meinem Leben 
bedanken: Danke für all Deine Liebe, Dein Verständnis, Deine unglaubliche 
Unterstützung und dafür, dass es mit Dir so schön ist, dass ich „nie darauf verzichten 
mag.“  
 
 
